<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='2527'><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="10999">KOA-18</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-26 14:53:02</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1995-09-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1610">Surfactant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26965">MaxPharma</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26965">MaxPharma</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-09-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="HT">Haiti</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19267">Pasteur Merieux Connaught Canada</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21398">Trustees of Health &amp; Hospitals of The City of Boston</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="21398">Trustees of Health &amp; Hospitals of The City of Boston</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18225">Massachusetts Institute of Technology</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="18225">Massachusetts Institute of Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="ES">Spain</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="TZ">Tanzania</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="TZ">Tanzania</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="12634">B-4157</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2000-05-15 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-05-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19142">Paligent Inc</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="19142">Paligent Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="140">DNA synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25333">Panacea Biotec Ltd</Company><Country id="IN">India</Country><Drug id="29616">Panacea-0394</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-20 00:00:00</LatestChange><ParentCompany id="25333">Panacea Biotec Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="139">DNA RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Country id="US">US</Country><Drug id="2973">DuP-105</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-03-02 00:00:00</LatestChange><ParentCompany id="15065">Bristol-Myers Squibb Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7213">Gastrointestinal diagnostic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18015">Medivir AB</Company><Country id="SE">Sweden</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="18015">Medivir AB</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20607">University of London</Company><Country id="GB">UK</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="20607">University of London</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20607">University of London</Company><Country id="GB">UK</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="20607">University of London</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27120">ANI Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39902">tuberculosis vaccine (BioVant), BioSante</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-23 00:00:00</LatestChange><ParentCompany id="27120">ANI Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-12-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="64334">Phospho MurNAc pentapeptide transferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="CH">Switzerland</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7813">TLR-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ZA">South Africa</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="372">Thymidylate synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036974">Tydockpharma Srl</Company><Country id="IT">Italy</Country><Drug id="59276">ThyX inhibitors (Helicobacter pylori/Mycobacterium tuberculosis infections), Tydockpharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-14 00:00:00</LatestChange><ParentCompany id="1036974">Tydockpharma Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="59885">CPZEN-45</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29830">Genexine Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="61171">GX-140</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-06-19 00:00:00</LatestChange><ParentCompany id="29830">Genexine Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1035256">Upstream Biosciences Inc</Company><Country id="CA">Canada</Country><Drug id="62917">antibacterial therapies (tuberculosis), Upstream Biosciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-01-10 00:00:00</LatestChange><ParentCompany id="1035256">Upstream Biosciences Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-01-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="68490">Isocitrate lyase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20573">Emory University</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034641">Shaheed Beheshti Medical University</Company><Country id="IR">Iran</Country><Drug id="65935">KBF-611</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-19 00:00:00</LatestChange><ParentCompany id="1034641">Shaheed Beheshti Medical University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1033991">Snowdon Inc</Company><Country id="US">US</Country><Drug id="64976">SND-159</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-05 00:00:00</LatestChange><ParentCompany id="1033991">Snowdon Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="66314">BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-04 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23924">Transgene SA</Company><Country id="FR">France</Country><Drug id="67820">Mycobacterium tuberculosis vaccine, Transgene</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-29 00:00:00</LatestChange><ParentCompany id="1020515">ACCRA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3958">Protein kinase G inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2011-01-23 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022846">Nagoya City University</Company><Country id="JP">Japan</Country><Drug id="70208">glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-18 00:00:00</LatestChange><ParentCompany id="1022846">Nagoya City University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022846">Nagoya City University</Company><Country id="JP">Japan</Country><Drug id="70208">glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-18 00:00:00</LatestChange><ParentCompany id="1022846">Nagoya City University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1062315">Pharmarare SA</Company><Country id="WO">World</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="1062315">Pharmarare SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-07-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6506">Thioredoxin reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061424">Intervet Innovation GmbH</Company><Country id="DE">Germany</Country><Drug id="70840">thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1061424">Intervet Innovation GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24984">Hans Knoell Institute of Natural Products Research</Company><Country id="DE">Germany</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="24984">Hans Knoell Institute of Natural Products Research</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="71430">Q-201, Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-17 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="71430">Q-201, Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-17 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24984">Hans Knoell Institute of Natural Products Research</Company><Country id="DE">Germany</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="24984">Hans Knoell Institute of Natural Products Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="520">Epimerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="CH">Switzerland</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="71115">ND-601</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23290">Texas A&amp;M University System</Company><Country id="US">US</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="23290">Texas A&amp;M University System</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51121">Eukaryotic initiation 2 alpha kinase 2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1037610">Numerate Inc</Company><Country id="US">US</Country><Drug id="73050">tuberculosis therapeutics, Numerate</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-21 00:00:00</LatestChange><ParentCompany id="1037610">Numerate Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1037610">Numerate Inc</Company><Country id="US">US</Country><Drug id="73050">tuberculosis therapeutics, Numerate</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-21 00:00:00</LatestChange><ParentCompany id="1037610">Numerate Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="74286">tuberculosis vaccine, TapImmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072312">Quantum Pharmaceuticals LLC</Company><Country id="RU">Russian Federation</Country><Drug id="76732">QP-42</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-24 00:00:00</LatestChange><ParentCompany id="1072312">Quantum Pharmaceuticals LLC</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042436">Orient Pharma Co Ltd</Company><Country id="TW">Taiwan</Country><Drug id="75681">tuberculosis therapeutics (capsule), Orient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-19 00:00:00</LatestChange><ParentCompany id="DOL1000087">Orient Europharma</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33999">Bifunctional aminoacyl tRNA synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="38419">miRNA agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="77124">MB-11, Microbion</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-17 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069315">VELES Pharma CJSC</Company><Country id="US">US</Country><Drug id="77247">recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-12 00:00:00</LatestChange><ParentCompany id="1069315">VELES Pharma CJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="86">Beta lactamase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-10-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24669">International Center for Genetic Engineering and Biotechnology (ICGEB)</Company><Country id="IT">Italy</Country><Drug id="78319">repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="24669">International Center for Genetic Engineering and Biotechnology (ICGEB)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24669">International Center for Genetic Engineering and Biotechnology (ICGEB)</Company><Country id="IT">Italy</Country><Drug id="78319">repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="24669">International Center for Genetic Engineering and Biotechnology (ICGEB)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="79395">NBTIs (Mycobacterium tuberculosis infection), iThemba</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-13 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-01-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25676">Universidade Federal de Minas Gerais</Company><Country id="BR">Brazil</Country><Drug id="79289">sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="25676">Universidade Federal de Minas Gerais</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25676">Universidade Federal de Minas Gerais</Company><Country id="BR">Brazil</Country><Drug id="79289">sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="25676">Universidade Federal de Minas Gerais</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80067">BCG vaccine (intradermal), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="26620">ATP-dependent Clp protease 2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031362">NovoBiotic Pharmaceuticals LLC</Company><Country id="US">US</Country><Drug id="81058">lassomycin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031362">NovoBiotic Pharmaceuticals LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80322">BCG vaccine (intradermal), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80322">BCG vaccine (intradermal), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80322">BCG vaccine (intradermal), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80322">BCG vaccine (intradermal), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1051">Unspecified enzyme modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86658">GA3 MEP-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="S">Suspended</Status><StatusDate>2000-02-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="BR">Brazil</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="S">Suspended</Status><StatusDate>2000-02-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1035490">Okairos</Company><Country id="IT">Italy</Country><Drug id="85469">tuberculosis vaccine, Okairos</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-30 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-05-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="87132">anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-27 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26884">State University of New York at Stony Brook</Company><Country id="US">US</Country><Drug id="88952">MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-02-17 00:00:00</LatestChange><ParentCompany id="26880">State University of New York</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-02-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26292">University of Tennessee</Company><Country id="US">US</Country><Drug id="88391">menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-04 00:00:00</LatestChange><ParentCompany id="26292">University of Tennessee</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="89141">rBCG30 vaccine (improved version, tuberculosis), UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-29 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="89337">recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="90381">anti-tuberculosis drugs (Mycobacterium tuberculosis infection), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="85843">Putative membrane protein mmpL3 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="89603">BM-212</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-20 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049946">BioNet-Asia Co Ltd</Company><Country id="TH">Thailand</Country><Drug id="91450">anti-tuberculosis vaccine, BioNet-Asia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-26 00:00:00</LatestChange><ParentCompany id="1049946">BioNet-Asia Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-26 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-03-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-03-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047078">Pharmstandard OJSC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="1047078">Pharmstandard OJSC</ParentCompany><Status id="R">Registered</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="UA">Ukraine</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PH">Philippines</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="VN">Vietnam</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1624">Alpha 1 antitrypsin modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009858">EpiVax Inc</Company><Country id="US">US</Country><Drug id="68339">T-cell epitope-based DNA vaccine (tuberculosis), EpiVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1009858">EpiVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27318">ID Pharma Co Ltd</Company><Country id="JP">Japan</Country><Drug id="70034">SeV gene vaccine (tuberculosis), DNAVEC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-02-08 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10236">Caspase recruitment domain protein-15 stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30837">Dartmouth-Hitchcock Medical Center</Company><Country id="US">US</Country><Drug id="90231">DAR-901</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-28 00:00:00</LatestChange><ParentCompany id="30837">Dartmouth-Hitchcock Medical Center</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-02-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="90432">CWGNC-4_1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-02 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="90432">CWGNC-4_1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-02 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-11-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="339">Protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28907">Microbiotix Inc</Company><Country id="US">US</Country><Drug id="76748">MBX-600</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-20 00:00:00</LatestChange><ParentCompany id="28907">Microbiotix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054637">iDialog</Company><Country id="RU">Russian Federation</Country><Drug id="76783">heterocyclic compounds (Mycobacterium tuberculosis), iDialog</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-21 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054637">iDialog</Company><Country id="RU">Russian Federation</Country><Drug id="76783">heterocyclic compounds (Mycobacterium tuberculosis), iDialog</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-21 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1009877">Chemical Diversity Research Institute Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1012947">ChemDiv Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1009877">Chemical Diversity Research Institute Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1012947">ChemDiv Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="18364">L-homoserine, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-07-24 13:56:01</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4917">Proteasome inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000375">Fudan University</Company><Country id="CN">China</Country><Drug id="67739">I-2906</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-01 00:00:00</LatestChange><ParentCompany id="DOL1000375">Fudan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000375">Fudan University</Company><Country id="CN">China</Country><Drug id="67739">I-2906</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-01 00:00:00</LatestChange><ParentCompany id="DOL1000375">Fudan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000375">Fudan University</Company><Country id="CN">China</Country><Drug id="67739">I-2906</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-01 00:00:00</LatestChange><ParentCompany id="DOL1000375">Fudan University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="S">Suspended</Status><StatusDate>2000-02-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="56894">streptomycin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-08-02 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-02-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-02-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="81330">rifampicin nanoparticles (tuberculosis), NPK Nanosistema</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-27 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30079">Chimerix Inc</Company><Country id="US">US</Country><Drug id="69571">Mycobacterium tuberculosis infection targeting compounds, Chimerix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-16 00:00:00</LatestChange><ParentCompany id="30079">Chimerix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="68316">MBS-103</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="382">TNF alpha synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080144">Procrysta Biologix Inc</Company><Country id="US">US</Country><Drug id="83811">PCB-101</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1080144">Procrysta Biologix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="4439">sparfloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="20268">Sumitomo Chemical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-11-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LT">Lithuania</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LT">Lithuania</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-10-29 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PE">Peru</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-11-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-12-22 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-09-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-09-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27371">Immunobiology Ltd</Company><Country id="GB">UK</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="27371">Immunobiology Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7992">Heat shock protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27371">Immunobiology Ltd</Company><Country id="GB">UK</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="27371">Immunobiology Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007281">L2 Diagnostics Llc</Company><Country id="US">US</Country><Drug id="72479">alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-02 00:00:00</LatestChange><ParentCompany id="1007281">L2 Diagnostics Llc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015643">Genvax Ltd</Company><Country id="GB">UK</Country><Drug id="57745">DNA vaccine (Mycobacterium tuberculosis infection), Genvax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-09-07 00:00:00</LatestChange><ParentCompany id="1003702">Medical Marketing International Group plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-09-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-12-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="ZA">South Africa</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="CH">Switzerland</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-01-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073514">The Vavilov Institute of General Genetics</Company><Country id="RU">Russian Federation</Country><Drug id="81211">microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1073514">The Vavilov Institute of General Genetics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="377">TGF beta antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="62253">Anticancer hormone</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-09-09 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="10997">PA-342</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-11-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 13:55:49</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="20226">Southern Research Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27485">Phage Therapeutics Inc</Company><Country id="US">US</Country><Drug id="34469">bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="27485">Phage Therapeutics Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5027">CD4 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7757">Natural killer cell stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5027">CD4 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7757">Natural killer cell stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2941">Antidepressant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-10-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2942">Anxiolytic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24317">Aquila Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X0">Africa</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-12-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X0">Africa</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-12-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-12-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-08-15 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-10-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-10-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-10 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060481">Mycosynthetix Inc</Company><Country id="US">US</Country><Drug id="70759">anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-12 00:00:00</LatestChange><ParentCompany id="1060481">Mycosynthetix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82710">cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="73547">Carbapenem</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1035636">INSERM Transfert</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</Company><Country id="CN">China</Country><Drug id="83764">small molecule antibiotic (Mycobacterium tuberculosis infection/Pseudomonas aeruginosa infection), Institute of Medicinal Biotechnology</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-19 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1012170">Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences</Company><Country id="CN">China</Country><Drug id="83764">small molecule antibiotic (Mycobacterium tuberculosis infection/Pseudomonas aeruginosa infection), Institute of Medicinal Biotechnology</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-19 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="78689">Mycobacterium tuberculosis MtrAB system inhibitors, Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-01 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="78689">Mycobacterium tuberculosis MtrAB system inhibitors, Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-01 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73188">BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73188">BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73188">BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071408">Alberta Glycomics Centre</Company><Country id="CA">Canada</Country><Drug id="79199">carbohydrate-based therapeutic agents (tuberculosis/mycobacterial infection), Alberta Glycomics Centre</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-06 00:00:00</LatestChange><ParentCompany id="1071408">Alberta Glycomics Centre</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071408">Alberta Glycomics Centre</Company><Country id="CA">Canada</Country><Drug id="79199">carbohydrate-based therapeutic agents (tuberculosis/mycobacterial infection), Alberta Glycomics Centre</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-06 00:00:00</LatestChange><ParentCompany id="1071408">Alberta Glycomics Centre</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1071865">Vivonyx Inc</Company><Country id="WO">World</Country><Drug id="79997">V-001, Vivonyx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="1071865">Vivonyx Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1071865">Vivonyx Inc</Company><Country id="WO">World</Country><Drug id="79997">V-001, Vivonyx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="1071865">Vivonyx Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1732">Energy metabolism modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1091260">Abera Bioscience AB</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="1091260">Abera Bioscience AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="89753">anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-31 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="89966">anti-tuberculosis therapeutics, Vertex Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="20739">Vertex Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6324">DXP reductoisomerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="89970">inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-30 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="77998">TB A series (tuberculosis infection), Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="77998">TB A series (tuberculosis infection), Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1457">Protein kinase C modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058778">Indian Institute of Integrative Medicine, Jammu</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058778">Indian Institute of Integrative Medicine, Jammu</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-01-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17684">Korea Research Institute of Chemical Technology</Company><Country id="KR">South Korea</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="17684">Korea Research Institute of Chemical Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-08-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6676">Arabinosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20649">Ohio State University</Company><Country id="US">US</Country><Drug id="17342">tuberculosis therapy, Ohio State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="20649">Ohio State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15542">Corixa Corp</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15542">Corixa Corp</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-03-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-01-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19595">Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004393">Myongji University (MJU)</Company><Country id="KR">South Korea</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1004393">Myongji University (MJU)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004393">Myongji University (MJU)</Company><Country id="KR">South Korea</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1004393">Myongji University (MJU)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-12-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-06-22 14:36:07</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24897">Antibiotic Co</Company><Country id="BG">Bulgaria</Country><Drug id="10994">T9</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-01-02 00:00:00</LatestChange><ParentCompany id="24897">Antibiotic Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24897">Antibiotic Co</Company><Country id="BG">Bulgaria</Country><Drug id="10994">T9</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-01-02 00:00:00</LatestChange><ParentCompany id="24897">Antibiotic Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-05-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-05-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20939">Whitehead Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="20939">Whitehead Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20939">Whitehead Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="20939">Whitehead Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21398">Trustees of Health &amp; Hospitals of The City of Boston</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="21398">Trustees of Health &amp; Hospitals of The City of Boston</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21398">Trustees of Health &amp; Hospitals of The City of Boston</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="21398">Trustees of Health &amp; Hospitals of The City of Boston</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="HT">Haiti</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="PE">Peru</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X0">Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X0">Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-10-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-10-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="ES">Spain</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-10-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-05-08 17:17:42</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="140">DNA synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-07-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7806">TLR-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25687">Wellesley College</Company><Country id="US">US</Country><Drug id="18382">antimycobacterials, Wellesley College</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="25687">Wellesley College</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25687">Wellesley College</Company><Country id="US">US</Country><Drug id="18382">antimycobacterials, Wellesley College</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="25687">Wellesley College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-07-24 15:57:33</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25333">Panacea Biotec Ltd</Company><Country id="IN">India</Country><Drug id="29616">Panacea-0394</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-20 00:00:00</LatestChange><ParentCompany id="25333">Panacea Biotec Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5720">Radiodiagnostic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18015">Medivir AB</Company><Country id="SE">Sweden</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="18015">Medivir AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-08-28 12:25:25</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27753">Oxxon Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="42764">TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-02 00:00:00</LatestChange><ParentCompany id="23434">Oxford BioMedica plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27753">Oxxon Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="42764">TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-02 00:00:00</LatestChange><ParentCompany id="23434">Oxford BioMedica plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-11-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="64334">Phospho MurNAc pentapeptide transferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="53605">rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-08 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2007-03-25 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56371">InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-03-21 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="143">Topoisomerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="143">Topoisomerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017551">Summit Plc</Company><Country id="GB">UK</Country><Drug id="57219">N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1017551">Summit Plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="416">Cytochrome P450 reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59777">ND-701</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59777">ND-701</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59784">ND-201</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1045576">Avanti Therapeutics</Company><Country id="WO">World</Country><Drug id="62573">tuberculosis vaccine, Avanti Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1045576">Avanti Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1035256">Upstream Biosciences Inc</Company><Country id="CA">Canada</Country><Drug id="62917">antibacterial therapies (tuberculosis), Upstream Biosciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-01-10 00:00:00</LatestChange><ParentCompany id="1035256">Upstream Biosciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20573">Emory University</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053537">Immune Solutions Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="66314">BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-04 00:00:00</LatestChange><ParentCompany id="1053537">Immune Solutions Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="GB">UK</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-08-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67090">nitroimidazole derivatives (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-06 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19368">Bio Farma</Company><Country id="ID">Indonesia</Country><Drug id="68627">Lipovax-Fg115-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-16 00:00:00</LatestChange><ParentCompany id="19368">Bio Farma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3983">Bacterial pathogenicity factor modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10360">A-G adenine DNA glycosylase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66921">Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36900">Protein tyrosine phosphatase beta inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><Drug id="72331">NTF-1836</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-05 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="71430">Q-201, Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-17 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-10-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014446">ImCure Therapeutics</Company><Country id="US">US</Country><Drug id="70838">184045</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1014446">ImCure Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="520">Epimerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24984">Hans Knoell Institute of Natural Products Research</Company><Country id="DE">Germany</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="24984">Hans Knoell Institute of Natural Products Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="CH">Switzerland</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015456">The Institute of Microbiology Chinese Academy of Sciences</Company><Country id="CN">China</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="23863">Chinese Academy of Sciences</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="74286">tuberculosis vaccine, TapImmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="75087">Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="38419">miRNA agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062884">Heber Biotec SA</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51201">Interferon gamma ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2008-02-11 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6324">DXP reductoisomerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26026">George Washington University</Company><Country id="US">US</Country><Drug id="79298">Dxr inhibitors (Mycobacterium tuberculosis infection), George Washington University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-12-01 00:00:00</LatestChange><ParentCompany id="26026">George Washington University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36223">Leucyl tRNA synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="78175">benzoxaborole Leucyl-tRNA synthase inhibitors (bacterial infection), Anacor</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-14 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="79395">NBTIs (Mycobacterium tuberculosis infection), iThemba</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-13 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="79395">NBTIs (Mycobacterium tuberculosis infection), iThemba</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-13 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-01-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031362">NovoBiotic Pharmaceuticals LLC</Company><Country id="US">US</Country><Drug id="81058">lassomycin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031362">NovoBiotic Pharmaceuticals LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1049303">Shanghai Sun-Sail Pharmaceutical Science &amp; Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="81181">ethylenediamine derivative (mycobacterium tuberculosis), Shanghai Sun-Sail Pharmaceutical Science &amp; Technology</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-31 00:00:00</LatestChange><ParentCompany id="19898">Shionogi &amp; Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="386">Vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81359">primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-04 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073327">AnHui Longcom Biologic Pharmacy Co Ltd</Company><Country id="CN">China</Country><Drug id="81363">AEC/BC02</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-21 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="82299">rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-07 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="85546">bacteria-based booster vaccine (tuberculosis), UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-15 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="BR">Brazil</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1997-10-21 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86658">GA3 MEP-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86659">GA4 NM-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86659">GA4 NM-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="87680">SKLB-TB37</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-16 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19060">Pantoate beta alanine ligase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="88214">pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="89824">urea compounds (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-23 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28506">Science &amp; Technology Corporation @ UNM</Company><Country id="US">US</Country><Drug id="88285">modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-05 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-05-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20639">University of New Mexico</Company><Country id="US">US</Country><Drug id="88285">modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-05 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="89141">rBCG30 vaccine (improved version, tuberculosis), UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-29 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003379">Sichuan University</Company><Country id="CN">China</Country><Drug id="95733">antituberculosis agents (tuberculosis) Sichuan University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-27 00:00:00</LatestChange><ParentCompany id="1003379">Sichuan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000150">University of Oslo</Company><Country id="NO">Norway</Country><Drug id="91534">prophylactic vaccine (tuberculosis), Vaccibody/University of Oslo</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-06-10 00:00:00</LatestChange><ParentCompany id="DOL1000150">University of Oslo</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1035099">Vaccibody AS</Company><Country id="NO">Norway</Country><Drug id="91534">prophylactic vaccine (tuberculosis), Vaccibody/University of Oslo</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-06-10 00:00:00</LatestChange><ParentCompany id="1015117">Bio-Medisinsk Innovasjon AS</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="11742">FtsZ protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="FR">France</Country><Drug id="92356">FtsZ inhibitors (Mycobacterium tuberculosis infection), Sanofi/Colorado State University/Stony Brook University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-15 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-04-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23137">Novartis AG</Company><Country id="US">US</Country><Drug id="91861">clofazimine (active tuberculosis), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-06-25 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-06-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-11-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1995-07-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1995-07-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-09-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PE">Peru</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TH">Thailand</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="IN">India</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1006860">Immunitor Inc</Company><Country id="UA">Ukraine</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="21412">Immune Network Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14240">Sarepta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="14240">Sarepta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14240">Sarepta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="14240">Sarepta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="21110">Karolinska Institutet</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-11-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6436">Enoyl ACP reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="AL">Albania</Country><Drug id="90085">PBTZ-169</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-27 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="90231">DAR-901</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-02-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="18364">L-homoserine, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-01-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047869">Only For Children Pharmaceuticals</Company><Country id="FR">France</Country><Drug id="91937">isoniazid (oral/solution, tuberculosis), O4CP</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-08 00:00:00</LatestChange><ParentCompany id="1047869">Only For Children Pharmaceuticals</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24136">Cornell University</Company><Country id="US">US</Country><Drug id="86500">proteosome inhibitors (mycobacterium tuberculosis), Cornell University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-01 00:00:00</LatestChange><ParentCompany id="24136">Cornell University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30079">Chimerix Inc</Company><Country id="US">US</Country><Drug id="69571">Mycobacterium tuberculosis infection targeting compounds, Chimerix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-16 00:00:00</LatestChange><ParentCompany id="30079">Chimerix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="68316">MBS-103</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="382">TNF alpha synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="4439">sparfloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="20268">Sumitomo Chemical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-11-20 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="4439">sparfloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="20268">Sumitomo Chemical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-07-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-07-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LT">Lithuania</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-10-29 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PE">Peru</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-11-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-11-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-12-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27371">Immunobiology Ltd</Company><Country id="GB">UK</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="27371">Immunobiology Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7992">Heat shock protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14513">Listeriolysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14513">Listeriolysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-09-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="518">Electron transport inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16277">Helmholtz Zentrum fur Infektionsforschung GmbH</Company><Country id="DE">Germany</Country><Drug id="82363">thuggacines (tuberculosis), Helmholtz</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-14 00:00:00</LatestChange><ParentCompany id="16277">Helmholtz Zentrum fur Infektionsforschung GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-05-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="518">Electron transport inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1050467">Ascenion GmbH</Company><Country id="DE">Germany</Country><Drug id="82363">thuggacines (tuberculosis), Helmholtz</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-14 00:00:00</LatestChange><ParentCompany id="1050467">Ascenion GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1089867">Create Vaccine Co</Company><Country id="JP">Japan</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1089867">Create Vaccine Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="71894">pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71894">pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51201">Interferon gamma ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073514">The Vavilov Institute of General Genetics</Company><Country id="RU">Russian Federation</Country><Drug id="81211">microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1073514">The Vavilov Institute of General Genetics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="10997">PA-342</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-11-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="NL">Netherlands</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70953">auxotroph vaccine (tuberculosis), Medicine in Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5449">CDw137 modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="56356">antibacterial diamines (tuberculosis), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="225">IL-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2941">Antidepressant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-05-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19075">STAT3 gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23270">New York Medical College</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="85542">methionine sulfoximine (tuberculosis), UCLA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1996-10-02 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-08-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-08-15 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X0">Africa</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-12-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-12-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-09-22 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7757">Natural killer cell stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="78400">spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-26 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="78400">spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-26 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28907">Microbiotix Inc</Company><Country id="US">US</Country><Drug id="78400">spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-26 00:00:00</LatestChange><ParentCompany id="28907">Microbiotix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82095">rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060481">Mycosynthetix Inc</Company><Country id="US">US</Country><Drug id="70759">anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-12 00:00:00</LatestChange><ParentCompany id="1060481">Mycosynthetix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="70759">anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-12 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="85843">Putative membrane protein mmpL3 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="89753">anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-31 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="89753">anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-31 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><Drug id="48519">clofazimine (oral cochleate formulation), BioDelivery</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-19 00:00:00</LatestChange><ParentCompany id="21164">BioDelivery Sciences International Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-02-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23373">ID Vaccine Corp</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-06-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061894">Maxwell Biotech Group</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061894">Maxwell Biotech Group</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-05-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20228">SPA Societa Prodotti Antibiotici SpA</Company><Country id="IT">Italy</Country><Drug id="9630">rifametane</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-26 00:00:00</LatestChange><ParentCompany id="20228">SPA Societa Prodotti Antibiotici SpA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-01-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-04-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19595">Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-01-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-06-22 14:36:07</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="955">Antimicrobial permeability enhancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1997-10-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-01-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="12633">B-4154</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="RU">Russian Federation</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="RU">Russian Federation</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="HT">Haiti</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="PE">Peru</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GE">Georgia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-10-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="ES">Spain</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="TZ">Tanzania</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19267">Pasteur Merieux Connaught Canada</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7812">TLR-4 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21048">Brigham &amp; Women's Hospital</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="21048">Brigham &amp; Women's Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19142">Paligent Inc</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="19142">Paligent Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25687">Wellesley College</Company><Country id="US">US</Country><Drug id="18382">antimycobacterials, Wellesley College</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="25687">Wellesley College</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-07-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="30452">antituberculosis agents, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-06-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-09-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7217">Autoimmune diagnostic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20607">University of London</Company><Country id="GB">UK</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="20607">University of London</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25333">Panacea Biotec Ltd</Company><Country id="IN">India</Country><Drug id="29616">Panacea-0394</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-20 00:00:00</LatestChange><ParentCompany id="25333">Panacea Biotec Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-07-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27120">ANI Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39902">tuberculosis vaccine (BioVant), BioSante</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-23 00:00:00</LatestChange><ParentCompany id="27120">ANI Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-05-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006466">FASgen Inc</Company><Country id="US">US</Country><Drug id="49581">FAS-20013</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="1006466">FASgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-04-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="IN">India</Country><Drug id="46560">RBx-8700</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-05 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-05-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="23008">6-aminoglycoside N-acetyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017551">Summit Plc</Company><Country id="GB">UK</Country><Drug id="57219">N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1017551">Summit Plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29103">Cumbre Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29103">Cumbre Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2006-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-06-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6436">Enoyl ACP reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56371">InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-03-21 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6436">Enoyl ACP reductase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56371">InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-03-21 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="X5">Europe</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="215">Interferon gamma receptor agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1035256">Upstream Biosciences Inc</Company><Country id="CA">Canada</Country><Drug id="62917">antibacterial therapies (tuberculosis), Upstream Biosciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-01-10 00:00:00</LatestChange><ParentCompany id="1035256">Upstream Biosciences Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-01-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59784">ND-201</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1045576">Avanti Therapeutics</Company><Country id="WO">World</Country><Drug id="62573">tuberculosis vaccine, Avanti Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1045576">Avanti Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1045576">Avanti Therapeutics</Company><Country id="WO">World</Country><Drug id="62573">tuberculosis vaccine, Avanti Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1045576">Avanti Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14851">Microbial Chemistry Research Foundation</Company><Country id="JP">Japan</Country><Drug id="59885">CPZEN-45</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="14851">Microbial Chemistry Research Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="59067">radezolid (oral, CAP/uSSSI), Melinta</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-15 00:00:00</LatestChange><ParentCompany id="29298">Melinta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-07-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1005984">Medisyn Technologies Inc</Company><Country id="US">US</Country><Drug id="65284">Gram positive antibacterials (tuberculosis infection), Medisyn Technologies</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-17 00:00:00</LatestChange><ParentCompany id="1005984">Medisyn Technologies Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><Drug id="69801">DF-152 series (Mycobacterium tuberculosis infection), Dafra Pharma R&amp;D</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-25 00:00:00</LatestChange><ParentCompany id="1031290">Dafra Pharma International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060609">LifePharms Inc</Company><Country id="US">US</Country><Drug id="70763">antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1060609">LifePharms Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053537">Immune Solutions Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="66314">BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-04 00:00:00</LatestChange><ParentCompany id="1053537">Immune Solutions Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022208">Reyon Pharmaceuticals Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="1022208">Reyon Pharmaceuticals Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004322">B&amp;C Biopharm</Company><Country id="KR">South Korea</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="1004322">B&amp;C Biopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20702">Wayne State University</Company><Country id="US">US</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="20702">Wayne State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6506">Thioredoxin reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061424">Intervet Innovation GmbH</Company><Country id="DE">Germany</Country><Drug id="70840">thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1061424">Intervet Innovation GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><Drug id="72331">NTF-1836</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-05 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66920">PknB inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66921">Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10360">A-G adenine DNA glycosylase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66921">Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71664">menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21239">Rutgers University</Company><Country id="US">US</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="21239">Rutgers University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="71115">ND-601</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015456">The Institute of Microbiology Chinese Academy of Sciences</Company><Country id="CN">China</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="23863">Chinese Academy of Sciences</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1033991">Snowdon Inc</Company><Country id="US">US</Country><Drug id="64976">SND-159</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-05 00:00:00</LatestChange><ParentCompany id="1033991">Snowdon Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="71115">ND-601</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017455">Ensoltek Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="71805">Hesed-1000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-10 00:00:00</LatestChange><ParentCompany id="1017455">Ensoltek Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17976">Novartis Vaccines and Diagnostics Ltd</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-02-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5486">CD40 ligand modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003225">Fundacao de Amparo a Pesquisa do Estado Sao Paulo</Company><Country id="BR">Brazil</Country><Drug id="71902">ruthenium (II) based organic complexes (tuberculosis infection), FAPESP</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-06-10 00:00:00</LatestChange><ParentCompany id="1003225">Fundacao de Amparo a Pesquisa do Estado Sao Paulo</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3983">Bacterial pathogenicity factor modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67299">FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1062315">Pharmarare SA</Company><Country id="WO">World</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="1062315">Pharmarare SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1050976">Sphaera Pharma</Company><Country id="IN">India</Country><Drug id="78319">repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1050976">Sphaera Pharma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27762">TapImmune Inc</Company><Country id="US">US</Country><Drug id="74286">tuberculosis vaccine, TapImmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="27762">TapImmune Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33963">Recombinant fungal vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1028690">Shreya Life Sciences Pvt Ltd</Company><Country id="IN">India</Country><Drug id="76688">anti-tuberculosis therapeutics, Shreya Life Sciences/NIO</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-03-30 00:00:00</LatestChange><ParentCompany id="1028690">Shreya Life Sciences Pvt Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80067">BCG vaccine (intradermal), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1064010">Quantum Pharmaceuticals Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76732">QP-42</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-24 00:00:00</LatestChange><ParentCompany id="1064010">Quantum Pharmaceuticals Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1064010">Quantum Pharmaceuticals Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76732">QP-42</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-24 00:00:00</LatestChange><ParentCompany id="1064010">Quantum Pharmaceuticals Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066884">Savine Therapeutics Pty Ltd</Company><Country id="AU">Australia</Country><Drug id="77428">TB SAVINE (cDNA vaccine, tuberculosis), Savine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-12-14 00:00:00</LatestChange><ParentCompany id="30212">BioDiem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25676">Universidade Federal de Minas Gerais</Company><Country id="BR">Brazil</Country><Drug id="79289">sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="25676">Universidade Federal de Minas Gerais</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1051">Unspecified enzyme modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21084">Howard Hughes Medical Institute</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="21084">Howard Hughes Medical Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20639">University of New Mexico</Company><Country id="US">US</Country><Drug id="88285">modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-05 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20520">National Institute of Allergy and Infectious Diseases</Company><Country id="TZ">Tanzania</Country><Drug id="83281">vaccine (disseminated tuberculosis), NIAID</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-11 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><Drug id="87565">Mycobacterium tuberculosis inhibitors (Mycobacterium tuberculosis infection), Eli Lilly</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-12 00:00:00</LatestChange><ParentCompany id="17810">Eli Lilly &amp; Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002785">Montana State University</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="1002785">Montana State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74361">DHNA octaprenyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1089655">University of Tennessee Research Foundation Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="88391">menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-04 00:00:00</LatestChange><ParentCompany id="26292">University of Tennessee</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="87680">SKLB-TB37</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-16 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-03-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="87132">anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-27 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="85546">bacteria-based booster vaccine (tuberculosis), UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-15 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071434">ActivBiotics Pharma LLC</Company><Country id="US">US</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="1071434">ActivBiotics Pharma LLC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="82052">Ubiquitin like protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20646">New York University</Company><Country id="US">US</Country><Drug id="88848">modified Pup modulators (Mycobacterium tuberculosis infection), New York University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-24 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="CN">China</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-09-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="349">Serine protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7302">Caspase-3 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1995-07-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-09-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="UA">Ukraine</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PE">Peru</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053349">Cumencor Pharmaceuticals</Company><Country id="CN">China</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="1053349">Cumencor Pharmaceuticals</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4917">Proteasome inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-05-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6436">Enoyl ACP reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-05-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2009-05-22 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="90231">DAR-901</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-02-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031545">SEEK</Company><Country id="GB">UK</Country><Drug id="90650">TB-v</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-12 00:00:00</LatestChange><ParentCompany id="1031545">SEEK</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="870">Glutamate receptor modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="18364">L-homoserine, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-07-24 13:56:01</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-06-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30079">Chimerix Inc</Company><Country id="US">US</Country><Drug id="69571">Mycobacterium tuberculosis infection targeting compounds, Chimerix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-16 00:00:00</LatestChange><ParentCompany id="30079">Chimerix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-11-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-04-28 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-04-28 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PE">Peru</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-11-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1052">Unspecified enzyme stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080144">Procrysta Biologix Inc</Company><Country id="US">US</Country><Drug id="83811">PCB-101</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1080144">Procrysta Biologix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-04-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14513">Listeriolysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-09-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="48680">Granulysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18210">Biowest Therapeutics Inc</Company><Country id="CA">Canada</Country><Drug id="9087">Penetrin-A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-11 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1994-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29482">Searchlight Minerals Corp</Company><Country id="GB">UK</Country><Drug id="39313">tuberculosis therapy, Phage Genomics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-04-29 00:00:00</LatestChange><ParentCompany id="29482">Searchlight Minerals Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29482">Searchlight Minerals Corp</Company><Country id="GB">UK</Country><Drug id="39313">tuberculosis therapy, Phage Genomics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-04-29 00:00:00</LatestChange><ParentCompany id="29482">Searchlight Minerals Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29482">Searchlight Minerals Corp</Company><Country id="GB">UK</Country><Drug id="39313">tuberculosis therapy, Phage Genomics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-04-29 00:00:00</LatestChange><ParentCompany id="29482">Searchlight Minerals Corp</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2005-04-29 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66922">UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36221">Leucyl tRNA synthetase modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015643">Genvax Ltd</Company><Country id="GB">UK</Country><Drug id="57745">DNA vaccine (Mycobacterium tuberculosis infection), Genvax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-09-07 00:00:00</LatestChange><ParentCompany id="1003702">Medical Marketing International Group plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15180">Topical antipruritic product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6589">Fatty acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71894">pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="US">US</Country><Drug id="85970">Q-203, Qurient / Infectex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-06 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="439">RNA synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="62255">Anticancer protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86108">pharmacophores (Mycobacterium tuberculosis), NIH</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-10-15 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19075">STAT3 gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-06-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-09-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-08-15 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="17424">vaccine (naked DNA, TB), Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-03 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-03-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="17424">vaccine (naked DNA, TB), Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-03 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-03-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2942">Anxiolytic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-10-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075252">Demuris Ltd</Company><Country id="GB">UK</Country><Drug id="81873">tuberculosis program, Demuris</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-16 00:00:00</LatestChange><ParentCompany id="1075252">Demuris Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075252">Demuris Ltd</Company><Country id="GB">UK</Country><Drug id="81873">tuberculosis program, Demuris</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-16 00:00:00</LatestChange><ParentCompany id="1075252">Demuris Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1035636">INSERM Transfert</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82095">rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2009-05-22 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="89970">inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-30 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="77998">TB A series (tuberculosis infection), Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73188">BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1470">Respiratory system agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1071865">Vivonyx Inc</Company><Country id="WO">World</Country><Drug id="79997">V-001, Vivonyx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="1071865">Vivonyx Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24385">University of Lille</Company><Country id="FR">France</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="24385">University of Lille</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24385">University of Lille</Company><Country id="FR">France</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="24385">University of Lille</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-09-22 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1470">Respiratory system agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032379">C&amp;O Pharmaceutical Technology (Holdings) Ltd</Company><Country id="HK">Hong Kong</Country><Drug id="61340">CO-12</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-08-31 00:00:00</LatestChange><ParentCompany id="19898">Shionogi &amp; Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12481">Interleukin-2 ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006553">EyeGene Inc</Company><Country id="KR">South Korea</Country><Drug id="93723">anti-tuberculosis vaccine, EyeGene</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-30 00:00:00</LatestChange><ParentCompany id="1006553">EyeGene Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20579">University of Georgia</Company><Country id="US">US</Country><Drug id="95507">small molecule therapeutics (tuberculosis/HIV), University of Georgia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-28 00:00:00</LatestChange><ParentCompany id="20579">University of Georgia</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-01-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-08-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23270">New York Medical College</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="731">Collagenase stimulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1052204">Beech Tree Labs Inc</Company><Country id="GB">UK</Country><Drug id="69033">ML-05</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-13 00:00:00</LatestChange><ParentCompany id="1052204">Beech Tree Labs Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061494">PharmaPraxis</Company><Country id="BR">Brazil</Country><Drug id="77481">TB-001</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-23 00:00:00</LatestChange><ParentCompany id="1061497">Axis Biotec Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061494">PharmaPraxis</Company><Country id="BR">Brazil</Country><Drug id="77481">TB-001</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-23 00:00:00</LatestChange><ParentCompany id="1061497">Axis Biotec Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-09-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23373">ID Vaccine Corp</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-06-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="248">Lyase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061894">Maxwell Biotech Group</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061894">Maxwell Biotech Group</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-04-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15542">Corixa Corp</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-03-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="59144">AERAS-405</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-09-18 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-09-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7992">Heat shock protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-07-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-06-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="85843">Putative membrane protein mmpL3 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="10999">KOA-18</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-26 14:53:02</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 14:53:02</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7812">TLR-4 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25562">VacTex Corp</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1999-10-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25562">VacTex Corp</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1999-10-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="135">DHFR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20265">Nventa Biopharmaceuticals Corp</Company><Country id="CA">Canada</Country><Drug id="12954">vaccine (tuberculosis), StressGen</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2000-05-18 00:00:00</LatestChange><ParentCompany id="1011141">Akela Pharma Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-05-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="12634">B-4157</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2000-05-15 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-05-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-05-08 17:17:42</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X2">Asia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="HT">Haiti</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="PE">Peru</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GE">Georgia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GE">Georgia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-02-10 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-02-10 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X0">Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-07-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25687">Wellesley College</Company><Country id="US">US</Country><Drug id="18382">antimycobacterials, Wellesley College</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="25687">Wellesley College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-07-24 15:57:33</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18015">Medivir AB</Company><Country id="SE">Sweden</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="18015">Medivir AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-08-28 12:25:25</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7212">Endocrine diagnostic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="53095">Macrophage mannose receptor 1 modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4156">Ultrasound contrast agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27120">ANI Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39902">tuberculosis vaccine (BioVant), BioSante</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-23 00:00:00</LatestChange><ParentCompany id="27120">ANI Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-05-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="53605">rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-08 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-07-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="64334">Phospho MurNAc pentapeptide transferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-06-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7806">TLR-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="18476">MAPK gene modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000424">Hosp Germans Trias i Pujol</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="DOL1000424">Hosp Germans Trias i Pujol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="59067">radezolid (oral, CAP/uSSSI), Melinta</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-15 00:00:00</LatestChange><ParentCompany id="29298">Melinta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="59067">radezolid (oral, CAP/uSSSI), Melinta</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-15 00:00:00</LatestChange><ParentCompany id="29298">Melinta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036974">Tydockpharma Srl</Company><Country id="IT">Italy</Country><Drug id="59276">ThyX inhibitors (Helicobacter pylori/Mycobacterium tuberculosis infections), Tydockpharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-14 00:00:00</LatestChange><ParentCompany id="1036974">Tydockpharma Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049288">TVAX Biomedical LLC</Company><Country id="US">US</Country><Drug id="64503">autologous therapeutic vaccine, TVAX Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="1049288">TVAX Biomedical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5486">CD40 ligand modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="62255">Anticancer protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10327">Protein tyrosine phosphatase-2C inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67299">FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67299">FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014446">ImCure Therapeutics</Company><Country id="US">US</Country><Drug id="70838">184045</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1014446">ImCure Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014446">ImCure Therapeutics</Company><Country id="US">US</Country><Drug id="70838">184045</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1014446">ImCure Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014446">ImCure Therapeutics</Company><Country id="US">US</Country><Drug id="70838">184045</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1014446">ImCure Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="553">Folate synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20659">University of Pittsburgh</Company><Country id="US">US</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20659">University of Pittsburgh</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004322">B&amp;C Biopharm</Company><Country id="KR">South Korea</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="1004322">B&amp;C Biopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="69074">BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="69074">BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017455">Ensoltek Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="71805">Hesed-1000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-10 00:00:00</LatestChange><ParentCompany id="1017455">Ensoltek Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20573">Emory University</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29586">THERAMetrics Holding AG</Company><Country id="CH">Switzerland</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="29586">THERAMetrics Holding AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51121">Eukaryotic initiation 2 alpha kinase 2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1037610">Numerate Inc</Company><Country id="US">US</Country><Drug id="73050">tuberculosis therapeutics, Numerate</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-21 00:00:00</LatestChange><ParentCompany id="1037610">Numerate Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-12-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1049303">Shanghai Sun-Sail Pharmaceutical Science &amp; Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="81181">ethylenediamine derivative (mycobacterium tuberculosis), Shanghai Sun-Sail Pharmaceutical Science &amp; Technology</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-31 00:00:00</LatestChange><ParentCompany id="19898">Shionogi &amp; Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053325">National Institute of Oceanography</Company><Country id="IN">India</Country><Drug id="76688">anti-tuberculosis therapeutics, Shreya Life Sciences/NIO</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-03-30 00:00:00</LatestChange><ParentCompany id="1053325">National Institute of Oceanography</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069315">VELES Pharma CJSC</Company><Country id="US">US</Country><Drug id="77247">recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-12 00:00:00</LatestChange><ParentCompany id="1069315">VELES Pharma CJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032094">ISA Pharmaceuticals BV</Company><Country id="NL">Netherlands</Country><Drug id="75383">TB-SLP</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-04-12 00:00:00</LatestChange><ParentCompany id="1032094">ISA Pharmaceuticals BV</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-04-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032094">ISA Pharmaceuticals BV</Company><Country id="NL">Netherlands</Country><Drug id="75383">TB-SLP</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-04-12 00:00:00</LatestChange><ParentCompany id="1032094">ISA Pharmaceuticals BV</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-04-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="922">Interferon gamma modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15190">Systemic dermatological antiviral product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="82584">tuberculosis therapy, NITD/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="386">Vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072842">National Institute for Food and Drug Control</Company><Country id="CN">China</Country><Drug id="81359">primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-04 00:00:00</LatestChange><ParentCompany id="1072842">National Institute for Food and Drug Control</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2012-05-04 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81363">AEC/BC02</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-21 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1050976">Sphaera Pharma</Company><Country id="IN">India</Country><Drug id="78319">repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1050976">Sphaera Pharma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="75087">Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="75087">Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="79294">Endopeptidase Clp inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031362">NovoBiotic Pharmaceuticals LLC</Company><Country id="US">US</Country><Drug id="81058">lassomycin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031362">NovoBiotic Pharmaceuticals LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-11-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="94475">accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-30 00:00:00</LatestChange><ParentCompany id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="94475">accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-30 00:00:00</LatestChange><ParentCompany id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-05-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86659">GA4 NM-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="88214">pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20520">National Institute of Allergy and Infectious Diseases</Company><Country id="TZ">Tanzania</Country><Drug id="83281">vaccine (disseminated tuberculosis), NIAID</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-11 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="84382">non-Leucyl-tRNA synthase inhibitors (tuberculosis infection), Anacor</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33569">Inhibin alpha chain inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26884">State University of New York at Stony Brook</Company><Country id="US">US</Country><Drug id="88952">MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-02-17 00:00:00</LatestChange><ParentCompany id="26880">State University of New York</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-02-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="17810">Eli Lilly &amp; Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20647">University of Auckland</Company><Country id="NZ">New Zealand</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20647">University of Auckland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86119">small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10583">Vitamin K epoxide reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86119">small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="89337">recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="82839">naphthoquinone compounds (Mycobacterium tuberculosis infection, natural product), University of Pretoria</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-15 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="82839">naphthoquinone compounds (Mycobacterium tuberculosis infection, natural product), University of Pretoria</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-15 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="87132">anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-27 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="154">Elastase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1732">Energy metabolism modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GB">UK</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-03-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009858">EpiVax Inc</Company><Country id="US">US</Country><Drug id="68339">T-cell epitope-based DNA vaccine (tuberculosis), EpiVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1009858">EpiVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009858">EpiVax Inc</Company><Country id="US">US</Country><Drug id="68339">T-cell epitope-based DNA vaccine (tuberculosis), EpiVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1009858">EpiVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1033227">MicuRx Pharmaceuticals Inc</Company><Country id="CN">China</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="1033227">MicuRx Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053349">Cumencor Pharmaceuticals</Company><Country id="CN">China</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="1053349">Cumencor Pharmaceuticals</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68371">PknB inhibitor (tuberculosis), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-15 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68371">PknB inhibitor (tuberculosis), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-15 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CN">China</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TR">Turkey</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TH">Thailand</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PH">Philippines</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PE">Peru</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="VN">Vietnam</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28907">Microbiotix Inc</Company><Country id="US">US</Country><Drug id="76748">MBX-600</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-20 00:00:00</LatestChange><ParentCompany id="28907">Microbiotix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12377">RNA vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27318">ID Pharma Co Ltd</Company><Country id="JP">Japan</Country><Drug id="70034">SeV gene vaccine (tuberculosis), DNAVEC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-02-08 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-06-14 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="CN">China</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-09-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1006860">Immunitor Inc</Company><Country id="UA">Ukraine</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="21412">Immune Network Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1006860">Immunitor Inc</Company><Country id="UA">Ukraine</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="21412">Immune Network Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="81330">rifampicin nanoparticles (tuberculosis), NPK Nanosistema</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-27 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="AL">Albania</Country><Drug id="90085">PBTZ-169</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-27 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068863">Silvius Pharma</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068863">Silvius Pharma</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031545">SEEK</Company><Country id="GB">UK</Country><Drug id="90650">TB-v</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-12 00:00:00</LatestChange><ParentCompany id="1031545">SEEK</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4917">Proteasome inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="30131">Janssen Diagnostics BVBA</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-05-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-02-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-02-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-02-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25631">Cincinnati Children's Hospital Medical Center</Company><Country id="US">US</Country><Drug id="81141">indoleamine 2,3-deoxygenase inhibitor (leishmaniasis/tuberculosis), Cincinnati Children's Hospital Medical Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-13 00:00:00</LatestChange><ParentCompany id="25631">Cincinnati Children's Hospital Medical Center</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080144">Procrysta Biologix Inc</Company><Country id="US">US</Country><Drug id="83811">PCB-101</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1080144">Procrysta Biologix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-04-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="68316">MBS-103</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-07-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EG">Egypt</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-10-29 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-11-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-09-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3616">FGF-2 ligand modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="18889">DNA binding protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="65858">BV-6481</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-22 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036156">Vaxil BioTherapeutics Ltd</Company><Country id="IL">Israel</Country><Drug id="66172">MTbuVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-25 00:00:00</LatestChange><ParentCompany id="1095293">Sheldonco Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6589">Fatty acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="71894">pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="11233">PA-647</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-10-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-10-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27371">Immunobiology Ltd</Company><Country id="GB">UK</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="27371">Immunobiology Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7992">Heat shock protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14365">Defensin modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1039453">Cellceutix Corp</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1039453">Cellceutix Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-12-22 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-12-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1039453">Cellceutix Corp</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1039453">Cellceutix Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="20226">Southern Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14513">Listeriolysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86108">pharmacophores (Mycobacterium tuberculosis), NIH</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27485">Phage Therapeutics Inc</Company><Country id="US">US</Country><Drug id="34469">bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="27485">Phage Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-06-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59776">ND-801</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015643">Genvax Ltd</Company><Country id="GB">UK</Country><Drug id="57745">DNA vaccine (Mycobacterium tuberculosis infection), Genvax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-09-07 00:00:00</LatestChange><ParentCompany id="1003702">Medical Marketing International Group plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PH">Philippines</Country><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-04-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19075">STAT3 gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="CH">Switzerland</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-01-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-10-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="225">IL-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-10-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="225">IL-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2942">Anxiolytic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-06-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-08-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-09-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="NL">Netherlands</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-10-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-10-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-09-22 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-10 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5039">T-cell surface glycoprotein CD8 stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="26034">RNA interference agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20579">University of Georgia</Company><Country id="US">US</Country><Drug id="95507">small molecule therapeutics (tuberculosis/HIV), University of Georgia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-28 00:00:00</LatestChange><ParentCompany id="20579">University of Georgia</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-01-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28802">GlobeImmune Inc</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="28802">GlobeImmune Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067932">University of Maryland Office of Technology Commercialization</Company><Country id="US">US</Country><Drug id="76032">tuberculosis vaccine, University of Maryland</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-10 00:00:00</LatestChange><ParentCompany id="20611">University of Maryland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59382">Alpha crystallin inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="72912">alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20228">SPA Societa Prodotti Antibiotici SpA</Company><Country id="IT">Italy</Country><Drug id="9630">rifametane</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-26 00:00:00</LatestChange><ParentCompany id="20228">SPA Societa Prodotti Antibiotici SpA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="248">Lyase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="77998">TB A series (tuberculosis infection), Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82095">rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2009-05-22 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82095">rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068758">California Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="1068758">California Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068758">California Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="1068758">California Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73188">BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24385">University of Lille</Company><Country id="FR">France</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="24385">University of Lille</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032379">C&amp;O Pharmaceutical Technology (Holdings) Ltd</Company><Country id="HK">Hong Kong</Country><Drug id="61340">CO-12</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-08-31 00:00:00</LatestChange><ParentCompany id="19898">Shionogi &amp; Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-08-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23270">New York Medical College</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-07-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="21014">Glutamine synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="85542">methionine sulfoximine (tuberculosis), UCLA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1996-10-02 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><Drug id="48519">clofazimine (oral cochleate formulation), BioDelivery</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-19 00:00:00</LatestChange><ParentCompany id="21164">BioDelivery Sciences International Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><Drug id="48519">clofazimine (oral cochleate formulation), BioDelivery</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-19 00:00:00</LatestChange><ParentCompany id="21164">BioDelivery Sciences International Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15542">Corixa Corp</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-01-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-20 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-08-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-02-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="10999">KOA-18</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-26 14:53:02</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1995-09-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-12-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26965">MaxPharma</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-09-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20939">Whitehead Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="20939">Whitehead Institute for Biomedical Research</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19267">Pasteur Merieux Connaught Canada</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="RU">Russian Federation</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X2">Asia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X2">Asia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="HT">Haiti</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GE">Georgia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-02-10 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-12-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-12-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26201">OriGenix Technologies Inc</Company><Country id="CA">Canada</Country><Drug id="32998">Mycobacterium tuberculosis therapeutics, OriGenix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-09-13 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-23 12:55:10</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18015">Medivir AB</Company><Country id="SE">Sweden</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="18015">Medivir AB</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Country id="US">US</Country><Drug id="2973">DuP-105</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-03-02 00:00:00</LatestChange><ParentCompany id="15065">Bristol-Myers Squibb Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="CH">Switzerland</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="CH">Switzerland</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006466">FASgen Inc</Company><Country id="US">US</Country><Drug id="49581">FAS-20013</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="1006466">FASgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="53605">rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-08 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-07-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-05-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2007-03-25 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000424">Hosp Germans Trias i Pujol</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="DOL1000424">Hosp Germans Trias i Pujol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034641">Shaheed Beheshti Medical University</Company><Country id="IR">Iran</Country><Drug id="65935">KBF-611</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-19 00:00:00</LatestChange><ParentCompany id="1034641">Shaheed Beheshti Medical University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="71664">menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21239">Rutgers University</Company><Country id="US">US</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="21239">Rutgers University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20647">University of Auckland</Company><Country id="NZ">New Zealand</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20647">University of Auckland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-02-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17976">Novartis Vaccines and Diagnostics Ltd</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="71115">ND-601</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="69074">BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7815">TLR-5 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19368">Bio Farma</Company><Country id="ID">Indonesia</Country><Drug id="68627">Lipovax-Fg115-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-16 00:00:00</LatestChange><ParentCompany id="19368">Bio Farma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1037610">Numerate Inc</Company><Country id="US">US</Country><Drug id="73050">tuberculosis therapeutics, Numerate</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-12-21 00:00:00</LatestChange><ParentCompany id="1037610">Numerate Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-12-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29586">THERAMetrics Holding AG</Company><Country id="CH">Switzerland</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="29586">THERAMetrics Holding AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1470">Respiratory system agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29586">THERAMetrics Holding AG</Company><Country id="CH">Switzerland</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="29586">THERAMetrics Holding AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21238">McMaster University</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="21238">McMaster University</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-07-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24987">University of Ghent</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="24987">University of Ghent</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="62253">Anticancer hormone</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="70763">antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27762">TapImmune Inc</Company><Country id="US">US</Country><Drug id="74286">tuberculosis vaccine, TapImmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="27762">TapImmune Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51207">Interleukin 12 ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="73315">tuberculosis ESX-3 gene expressing Mycobacterium smegmatis vaccine, Albert Einstein College of Medicine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-06-21 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66920">PknB inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="520">Epimerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="CH">Switzerland</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062884">Heber Biotec SA</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="82299">rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-07 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26026">George Washington University</Company><Country id="US">US</Country><Drug id="79298">Dxr inhibitors (Mycobacterium tuberculosis infection), George Washington University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-12-01 00:00:00</LatestChange><ParentCompany id="26026">George Washington University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="78175">benzoxaborole Leucyl-tRNA synthase inhibitors (bacterial infection), Anacor</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-14 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="386">Vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073327">AnHui Longcom Biologic Pharmacy Co Ltd</Company><Country id="CN">China</Country><Drug id="81359">primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-04 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073327">AnHui Longcom Biologic Pharmacy Co Ltd</Company><Country id="CN">China</Country><Drug id="81363">AEC/BC02</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-21 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36223">Leucyl tRNA synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17639">Kaneka Corp</Company><Country id="JP">Japan</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="17639">Kaneka Corp</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="89603">BM-212</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-20 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071434">ActivBiotics Pharma LLC</Company><Country id="US">US</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="1071434">ActivBiotics Pharma LLC</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86658">GA3 MEP-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049946">BioNet-Asia Co Ltd</Company><Country id="TH">Thailand</Country><Drug id="91450">anti-tuberculosis vaccine, BioNet-Asia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-26 00:00:00</LatestChange><ParentCompany id="1049946">BioNet-Asia Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-26 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28506">Science &amp; Technology Corporation @ UNM</Company><Country id="US">US</Country><Drug id="88285">modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-05 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-05-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86055">thiatetracosanoate analogs (Mycobacterium tuberculosis), National Institutes of Health</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86055">thiatetracosanoate analogs (Mycobacterium tuberculosis), National Institutes of Health</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002785">Montana State University</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="1002785">Montana State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="17810">Eli Lilly &amp; Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28506">Science &amp; Technology Corporation @ UNM</Company><Country id="US">US</Country><Drug id="88384">peptides (tuberculosis), University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-24 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28506">Science &amp; Technology Corporation @ UNM</Company><Country id="US">US</Country><Drug id="88384">peptides (tuberculosis), University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-24 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1089655">University of Tennessee Research Foundation Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="88391">menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-04 00:00:00</LatestChange><ParentCompany id="26292">University of Tennessee</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74361">DHNA octaprenyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26292">University of Tennessee</Company><Country id="US">US</Country><Drug id="88391">menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-04 00:00:00</LatestChange><ParentCompany id="26292">University of Tennessee</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1027030">Amneal Pharmaceutical LLC</Company><Country id="IN">India</Country><Drug id="95732">antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-28 00:00:00</LatestChange><ParentCompany id="1027030">Amneal Pharmaceutical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1027030">Amneal Pharmaceutical LLC</Company><Country id="IN">India</Country><Drug id="95732">antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-28 00:00:00</LatestChange><ParentCompany id="1027030">Amneal Pharmaceutical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="10583">Vitamin K epoxide reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86119">small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="90122">DprE1 inhibitors (Mycobacterium tuberculosis infection), AstraZeneca</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1996-12-09 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2009-05-22 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="379">Trypsin inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047078">Pharmstandard OJSC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="1047078">Pharmstandard OJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-01-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="JP">Japan</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="JP">Japan</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-04-19 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CN">China</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="EU">EU</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-03-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><Drug id="30799">Mycobacterium chaperonin inhibitors, University of Bristol</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-20 00:00:00</LatestChange><ParentCompany id="20544">University of Bristol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29481">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-10-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29482">Searchlight Minerals Corp</Company><Country id="GB">UK</Country><Drug id="39313">tuberculosis therapy, Phage Genomics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-04-29 00:00:00</LatestChange><ParentCompany id="29482">Searchlight Minerals Corp</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2005-04-29 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-06-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="68316">MBS-103</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="11233">PA-647</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-10-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-10-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1052">Unspecified enzyme stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080144">Procrysta Biologix Inc</Company><Country id="US">US</Country><Drug id="83811">PCB-101</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1080144">Procrysta Biologix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="56894">streptomycin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-08-02 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-08-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="81330">rifampicin nanoparticles (tuberculosis), NPK Nanosistema</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-27 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="81330">rifampicin nanoparticles (tuberculosis), NPK Nanosistema</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-27 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18210">Biowest Therapeutics Inc</Company><Country id="CA">Canada</Country><Drug id="9087">Penetrin-A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-11 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1994-07-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18210">Biowest Therapeutics Inc</Company><Country id="CA">Canada</Country><Drug id="9087">Penetrin-A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-11 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18210">Biowest Therapeutics Inc</Company><Country id="CA">Canada</Country><Drug id="9087">Penetrin-A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-11 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="71741">TL1 inhibitors (tuberculosis infection), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-11-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="4439">sparfloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="20268">Sumitomo Chemical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-11-20 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="30365">Ubiquinol cytochrome C reductase 14 kDa inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="US">US</Country><Drug id="85970">Q-203, Qurient / Infectex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-06 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73038">polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-09 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66922">UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-11-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-11-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LT">Lithuania</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-04-28 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EG">Egypt</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EG">Egypt</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14513">Listeriolysin stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7996">Hsp 60 family stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="ES">Spain</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="ES">Spain</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="CH">Switzerland</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-01-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031352">National Institute of Biomedical Innovation</Company><Country id="JP">Japan</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1031352">National Institute of Biomedical Innovation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073514">The Vavilov Institute of General Genetics</Company><Country id="RU">Russian Federation</Country><Drug id="81211">microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1073514">The Vavilov Institute of General Genetics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073514">The Vavilov Institute of General Genetics</Company><Country id="RU">Russian Federation</Country><Drug id="81211">microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1073514">The Vavilov Institute of General Genetics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043700">PharMida AG</Company><Country id="CH">Switzerland</Country><Drug id="66235">targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-06 00:00:00</LatestChange><ParentCompany id="1011432">Midatech Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-02-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-02-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015643">Genvax Ltd</Company><Country id="GB">UK</Country><Drug id="57745">DNA vaccine (Mycobacterium tuberculosis infection), Genvax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-09-07 00:00:00</LatestChange><ParentCompany id="1003702">Medical Marketing International Group plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-09-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-05-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="10997">PA-342</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-11-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="17424">vaccine (naked DNA, TB), Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-03 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-03-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CH">Switzerland</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-10-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="NL">Netherlands</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-09-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-09-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-09-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-12-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28802">GlobeImmune Inc</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="28802">GlobeImmune Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28802">GlobeImmune Inc</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="28802">GlobeImmune Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28802">GlobeImmune Inc</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="28802">GlobeImmune Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-08-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-08-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-08-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59">Androgen receptor agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23270">New York Medical College</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="59144">AERAS-405</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-09-18 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17684">Korea Research Institute of Chemical Technology</Company><Country id="KR">South Korea</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="17684">Korea Research Institute of Chemical Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17684">Korea Research Institute of Chemical Technology</Company><Country id="KR">South Korea</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="17684">Korea Research Institute of Chemical Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1035636">INSERM Transfert</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76813">anti-tuberculosis therapeutics, Pro Bono Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-17 00:00:00</LatestChange><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-07-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76813">anti-tuberculosis therapeutics, Pro Bono Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-17 00:00:00</LatestChange><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-07-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-06-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1833">Non-nucleoside reverse transcriptase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-09-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="89966">anti-tuberculosis therapeutics, Vertex Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="20739">Vertex Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6324">DXP reductoisomerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="89970">inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-30 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="72912">alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058778">Indian Institute of Integrative Medicine, Jammu</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6676">Arabinosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20649">Ohio State University</Company><Country id="US">US</Country><Drug id="17342">tuberculosis therapy, Ohio State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="20649">Ohio State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-03-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20649">Ohio State University</Company><Country id="US">US</Country><Drug id="17342">tuberculosis therapy, Ohio State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="20649">Ohio State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="85843">Putative membrane protein mmpL3 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-20 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21398">Trustees of Health &amp; Hospitals of The City of Boston</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="21398">Trustees of Health &amp; Hospitals of The City of Boston</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18225">Massachusetts Institute of Technology</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="18225">Massachusetts Institute of Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-02-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1610">Surfactant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1997-10-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="135">DHFR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-12-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26965">MaxPharma</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="11526">M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-28 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-01-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="12633">B-4154</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="439">RNA synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-03-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="PE">Peru</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GE">Georgia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-02-10 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="ZA">South Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-02-10 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="TZ">Tanzania</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><Drug id="15102">rifapentine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-02 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-10-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6565">3-Oxoacyl-ACP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="30452">antituberculosis agents, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-06-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6565">3-Oxoacyl-ACP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="30452">antituberculosis agents, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-06-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-09-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7210">Cardiovascular diagnostic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18471">Navidea Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="34061">technetium Tc 99m tilmanocept</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-12 00:00:00</LatestChange><ParentCompany id="18471">Navidea Biopharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="FI">Finland</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-06-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7806">TLR-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-01-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15350">Central Drug Research Institute</Company><Country id="IN">India</Country><Drug id="50637">galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-24 00:00:00</LatestChange><ParentCompany id="15561">Council of Scientific and Industrial Research (India)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="23008">6-aminoglycoside N-acetyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="57219">N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000424">Hosp Germans Trias i Pujol</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="DOL1000424">Hosp Germans Trias i Pujol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000424">Hosp Germans Trias i Pujol</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="DOL1000424">Hosp Germans Trias i Pujol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="X5">Europe</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="X5">Europe</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="59885">CPZEN-45</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29103">Cumbre Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29103">Cumbre Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2006-09-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-05-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2007-03-25 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049288">TVAX Biomedical LLC</Company><Country id="US">US</Country><Drug id="64503">autologous therapeutic vaccine, TVAX Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="1049288">TVAX Biomedical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049288">TVAX Biomedical LLC</Company><Country id="US">US</Country><Drug id="64503">autologous therapeutic vaccine, TVAX Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="1049288">TVAX Biomedical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="68490">Isocitrate lyase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20573">Emory University</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67295">EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67299">FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="336">Protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022208">Reyon Pharmaceuticals Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="1022208">Reyon Pharmaceuticals Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="GB">UK</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-08-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9671">Unspecified protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66920">PknB inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66921">Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71664">menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23290">Texas A&amp;M University System</Company><Country id="US">US</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="23290">Texas A&amp;M University System</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-09-20 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072312">Quantum Pharmaceuticals LLC</Company><Country id="RU">Russian Federation</Country><Drug id="76732">QP-42</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-24 00:00:00</LatestChange><ParentCompany id="1072312">Quantum Pharmaceuticals LLC</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015456">The Institute of Microbiology Chinese Academy of Sciences</Company><Country id="CN">China</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="23863">Chinese Academy of Sciences</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003225">Fundacao de Amparo a Pesquisa do Estado Sao Paulo</Company><Country id="BR">Brazil</Country><Drug id="71902">ruthenium (II) based organic complexes (tuberculosis infection), FAPESP</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-06-10 00:00:00</LatestChange><ParentCompany id="1003225">Fundacao de Amparo a Pesquisa do Estado Sao Paulo</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-06-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1053325">National Institute of Oceanography</Company><Country id="IN">India</Country><Drug id="76688">anti-tuberculosis therapeutics, Shreya Life Sciences/NIO</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-03-30 00:00:00</LatestChange><ParentCompany id="1053325">National Institute of Oceanography</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1028690">Shreya Life Sciences Pvt Ltd</Company><Country id="IN">India</Country><Drug id="76688">anti-tuberculosis therapeutics, Shreya Life Sciences/NIO</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-03-30 00:00:00</LatestChange><ParentCompany id="1028690">Shreya Life Sciences Pvt Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="74814">gyrase B inhibitors (tuberculosis), SRI</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-02 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-11-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23924">Transgene SA</Company><Country id="FR">France</Country><Drug id="67820">Mycobacterium tuberculosis vaccine, Transgene</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-29 00:00:00</LatestChange><ParentCompany id="1020515">ACCRA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><Drug id="6934">edodekin alfa</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-06-27 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-06-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="70763">antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060609">LifePharms Inc</Company><Country id="US">US</Country><Drug id="70763">antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1060609">LifePharms Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-16 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061424">Intervet Innovation GmbH</Company><Country id="DE">Germany</Country><Drug id="70840">thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1061424">Intervet Innovation GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061424">Intervet Innovation GmbH</Company><Country id="DE">Germany</Country><Drug id="70840">thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-26 00:00:00</LatestChange><ParentCompany id="1061424">Intervet Innovation GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062637">New Medicines for Tuberculosis</Company><Country id="CH">Switzerland</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1062637">New Medicines for Tuberculosis</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042436">Orient Pharma Co Ltd</Company><Country id="TW">Taiwan</Country><Drug id="75681">tuberculosis therapeutics (capsule), Orient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-19 00:00:00</LatestChange><ParentCompany id="DOL1000087">Orient Europharma</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><Drug id="72331">NTF-1836</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-05 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="75087">Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36223">Leucyl tRNA synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33999">Bifunctional aminoacyl tRNA synthetase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1065893">Omnia Molecular</Company><Country id="ES">Spain</Country><Drug id="75760">leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1065893">Omnia Molecular</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51201">Interferon gamma ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062884">Heber Biotec SA</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2008-02-11 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="82299">rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-07 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069315">VELES Pharma CJSC</Company><Country id="US">US</Country><Drug id="77247">recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-12 00:00:00</LatestChange><ParentCompany id="1069315">VELES Pharma CJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="84382">non-Leucyl-tRNA synthase inhibitors (tuberculosis infection), Anacor</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066884">Savine Therapeutics Pty Ltd</Company><Country id="AU">Australia</Country><Drug id="77428">TB SAVINE (cDNA vaccine, tuberculosis), Savine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-12-14 00:00:00</LatestChange><ParentCompany id="30212">BioDiem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20647">University of Auckland</Company><Country id="NZ">New Zealand</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20647">University of Auckland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="84564">ChAdOx1-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-12 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20646">New York University</Company><Country id="US">US</Country><Drug id="88848">modified Pup modulators (Mycobacterium tuberculosis infection), New York University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-24 00:00:00</LatestChange><ParentCompany id="20646">New York University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="88214">pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="79288">Enoyl ACP reductase Fabl inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26884">State University of New York at Stony Brook</Company><Country id="US">US</Country><Drug id="88952">MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-02-17 00:00:00</LatestChange><ParentCompany id="26880">State University of New York</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-02-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><Drug id="87565">Mycobacterium tuberculosis inhibitors (Mycobacterium tuberculosis infection), Eli Lilly</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-12 00:00:00</LatestChange><ParentCompany id="17810">Eli Lilly &amp; Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034429">Saurashtra University</Company><Country id="IN">India</Country><Drug id="95732">antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-28 00:00:00</LatestChange><ParentCompany id="1034429">Saurashtra University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19368">Bio Farma</Company><Country id="ID">Indonesia</Country><Drug id="96406">Lipovax-FliC-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-16 00:00:00</LatestChange><ParentCompany id="19368">Bio Farma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-03-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1996-12-09 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1996-12-09 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="94475">accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-30 00:00:00</LatestChange><ParentCompany id="1071244">Changchun ChangSheng Gene Pharmaceutical Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-04-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047869">Only For Children Pharmaceuticals</Company><Country id="FR">France</Country><Drug id="91937">isoniazid (oral/solution, tuberculosis), O4CP</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-08 00:00:00</LatestChange><ParentCompany id="1047869">Only For Children Pharmaceuticals</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047078">Pharmstandard OJSC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="1047078">Pharmstandard OJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-01-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="EU">EU</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-08-31 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="EU">EU</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-08-31 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PE">Peru</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PH">Philippines</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="PH">Philippines</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TH">Thailand</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KE">Kenya</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="JP">Japan</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2015-03-18 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CO">Colombia</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86146">mycothiol-S-conjugate amidase inhibitors (Mycobacterium tuberculosis infection), National Institutes of Health</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="30242">Mycothiol conjugate amidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="86146">mycothiol-S-conjugate amidase inhibitors (Mycobacterium tuberculosis infection), National Institutes of Health</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6366">Indoleamine-pyrrole-2,3-dioxygenase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25631">Cincinnati Children's Hospital Medical Center</Company><Country id="US">US</Country><Drug id="81141">indoleamine 2,3-deoxygenase inhibitor (leishmaniasis/tuberculosis), Cincinnati Children's Hospital Medical Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-13 00:00:00</LatestChange><ParentCompany id="25631">Cincinnati Children's Hospital Medical Center</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1006860">Immunitor Inc</Company><Country id="UA">Ukraine</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="21412">Immune Network Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16299">Genzyme Corp</Company><Country id="US">US</Country><Drug id="47123">enoyl reductase inhibitors (antimicrobial), Genzyme</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-05-25 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-05-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><Drug id="30799">Mycobacterium chaperonin inhibitors, University of Bristol</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-20 00:00:00</LatestChange><ParentCompany id="20544">University of Bristol</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><Drug id="30799">Mycobacterium chaperonin inhibitors, University of Bristol</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-20 00:00:00</LatestChange><ParentCompany id="20544">University of Bristol</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-03-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1732">Energy metabolism modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20658">University of Pennsylvania</Company><Country id="US">US</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="20658">University of Pennsylvania</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7826">TLR-9 modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29958">Innate Immunotherapeutics Ltd</Company><Country id="US">US</Country><Drug id="60213">MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-12 00:00:00</LatestChange><ParentCompany id="29958">Innate Immunotherapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-12-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1033227">MicuRx Pharmaceuticals Inc</Company><Country id="CN">China</Country><Drug id="68345">antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-06 00:00:00</LatestChange><ParentCompany id="1033227">MicuRx Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="30131">Janssen Diagnostics BVBA</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29481">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-10-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5552">Helicase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66922">UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30079">Chimerix Inc</Company><Country id="US">US</Country><Drug id="69571">Mycobacterium tuberculosis infection targeting compounds, Chimerix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-16 00:00:00</LatestChange><ParentCompany id="30079">Chimerix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="GB">UK</Country><Drug id="10211">amikacin (liposomal formulation), NeXstar</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-25 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-06-25 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1009877">Chemical Diversity Research Institute Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1012947">ChemDiv Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-02-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="11233">PA-647</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-10-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-11-02 15:31:09</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068863">Silvius Pharma</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-08-14 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="86639">indazole derivatives (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-12-22 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1540">Macrolide antibiotic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16277">Helmholtz Zentrum fur Infektionsforschung GmbH</Company><Country id="DE">Germany</Country><Drug id="82363">thuggacines (tuberculosis), Helmholtz</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-14 00:00:00</LatestChange><ParentCompany id="16277">Helmholtz Zentrum fur Infektionsforschung GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-05-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="664">Fibrosuppressant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="858">Collagen synthesis modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="82709">macrolides (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-09-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-12-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="PH">Philippines</Country><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-04-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-07-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4965">IL12 gene stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-04-28 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PH">Philippines</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EG">Egypt</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="CH">Switzerland</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-01-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-10-15 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="65858">BV-6481</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-22 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="85970">Q-203, Qurient / Infectex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-06 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24317">Aquila Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36221">Leucyl tRNA synthetase modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="36221">Leucyl tRNA synthetase modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-10-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59776">ND-801</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="33132">B-4128</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-07-08 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-03-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1885">Phospholipase A2 stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="33132">B-4128</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-07-08 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-07-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14365">Defensin modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5039">T-cell surface glycoprotein CD8 stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-10-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27485">Phage Therapeutics Inc</Company><Country id="US">US</Country><Drug id="34469">bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="27485">Phage Therapeutics Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073122">University of Illinois at Urbana-Champaign</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-06-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-03-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-10-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032379">C&amp;O Pharmaceutical Technology (Holdings) Ltd</Company><Country id="HK">Hong Kong</Country><Drug id="61340">CO-12</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-08-31 00:00:00</LatestChange><ParentCompany id="19898">Shionogi &amp; Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7052">Cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1091260">Abera Bioscience AB</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="1091260">Abera Bioscience AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28907">Microbiotix Inc</Company><Country id="US">US</Country><Drug id="78400">spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-26 00:00:00</LatestChange><ParentCompany id="28907">Microbiotix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-08-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-05-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-08-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-08-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="59144">AERAS-405</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-09-18 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-04-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-07-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1732">Energy metabolism modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59">Androgen receptor agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-11-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><Drug id="48519">clofazimine (oral cochleate formulation), BioDelivery</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-19 00:00:00</LatestChange><ParentCompany id="21164">BioDelivery Sciences International Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-06-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="89552">mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-20 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="248">Lyase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19595">Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-01-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-02-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-10-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-10-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="ES">Spain</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9320">Topoisomerase IV inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18225">Massachusetts Institute of Technology</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="18225">Massachusetts Institute of Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18225">Massachusetts Institute of Technology</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="18225">Massachusetts Institute of Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1291">Cytokine release modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2001-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1593">Antimicrobial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-02-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1997-10-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="10999">KOA-18</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-26 14:53:02</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 14:53:02</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="955">Antimicrobial permeability enhancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15585">CytRx Corporation</Company><Country id="US">US</Country><Drug id="11007">CRL-1018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1995-09-27 00:00:00</LatestChange><ParentCompany id="15585">CytRx Corporation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="RU">Russian Federation</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X0">Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21235">Georgia State University</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="21235">Georgia State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7806">TLR-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083670">Farmabrasilis</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="1083670">Farmabrasilis</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24983">Universidade Estadual de Campinas</Company><Country id="BR">Brazil</Country><Drug id="15596">P-MAPA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="24983">Universidade Estadual de Campinas</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19142">Paligent Inc</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="19142">Paligent Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19142">Paligent Inc</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="19142">Paligent Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25562">VacTex Corp</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26201">OriGenix Technologies Inc</Company><Country id="CA">Canada</Country><Drug id="32998">Mycobacterium tuberculosis therapeutics, OriGenix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-09-13 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-09-13 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="AT">Austria</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="30452">antituberculosis agents, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-06-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27753">Oxxon Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="42764">TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-02 00:00:00</LatestChange><ParentCompany id="23434">Oxford BioMedica plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-11-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27120">ANI Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39902">tuberculosis vaccine (BioVant), BioSante</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-23 00:00:00</LatestChange><ParentCompany id="27120">ANI Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-12-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23741">NicOx SA</Company><Country id="FR">France</Country><Drug id="47140">NCX-976</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-01-31 00:00:00</LatestChange><ParentCompany id="23741">NicOx SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="SE">Sweden</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-12-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006466">FASgen Inc</Company><Country id="US">US</Country><Drug id="49581">FAS-20013</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="1006466">FASgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-08-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-07-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-05-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7828">TLR-9 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="215">Interferon gamma receptor agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7828">TLR-9 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="X0">Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-09-30 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="GB">UK</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="X5">Europe</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-05-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ZA">South Africa</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="416">Cytochrome P450 reductase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59777">ND-701</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59777">ND-701</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59784">ND-201</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59784">ND-201</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14851">Microbial Chemistry Research Foundation</Company><Country id="JP">Japan</Country><Drug id="59885">CPZEN-45</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="14851">Microbial Chemistry Research Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29830">Genexine Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="61171">GX-140</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-06-19 00:00:00</LatestChange><ParentCompany id="29830">Genexine Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-06-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29830">Genexine Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="61171">GX-140</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-06-19 00:00:00</LatestChange><ParentCompany id="29830">Genexine Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67295">EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="40557">Non receptor tyrosine phosphatase 22 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20659">University of Pittsburgh</Company><Country id="US">US</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20659">University of Pittsburgh</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19368">Bio Farma</Company><Country id="ID">Indonesia</Country><Drug id="68627">Lipovax-Fg115-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-16 00:00:00</LatestChange><ParentCompany id="19368">Bio Farma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><Drug id="69801">DF-152 series (Mycobacterium tuberculosis infection), Dafra Pharma R&amp;D</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-25 00:00:00</LatestChange><ParentCompany id="1031290">Dafra Pharma International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9671">Unspecified protein kinase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66920">PknB inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-23 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034641">Shaheed Beheshti Medical University</Company><Country id="IR">Iran</Country><Drug id="65935">KBF-611</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-19 00:00:00</LatestChange><ParentCompany id="1034641">Shaheed Beheshti Medical University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="GB">UK</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-08-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007058">Imaxio</Company><Country id="FR">France</Country><Drug id="66409">IMX-461</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-01 00:00:00</LatestChange><ParentCompany id="1007058">Imaxio</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-02-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="GB">UK</Country><Drug id="63673">FP-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049288">TVAX Biomedical LLC</Company><Country id="US">US</Country><Drug id="64503">autologous therapeutic vaccine, TVAX Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="1049288">TVAX Biomedical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-16 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="520">Epimerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24984">Hans Knoell Institute of Natural Products Research</Company><Country id="DE">Germany</Country><Drug id="70901">benzothiazinones (tuberculosis), Hans Knoell Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="24984">Hans Knoell Institute of Natural Products Research</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="73315">tuberculosis ESX-3 gene expressing Mycobacterium smegmatis vaccine, Albert Einstein College of Medicine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-06-21 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33963">Recombinant fungal vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73326">Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-15 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><Drug id="72331">NTF-1836</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-05 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-10 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71698">RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="IN">India</Country><Drug id="71700">gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="73547">Carbapenem</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-10-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20647">University of Auckland</Company><Country id="NZ">New Zealand</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20647">University of Auckland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75152">ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="77124">MB-11, Microbion</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-17 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="77124">MB-11, Microbion</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-17 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069315">VELES Pharma CJSC</Company><Country id="US">US</Country><Drug id="77247">recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-12 00:00:00</LatestChange><ParentCompany id="1069315">VELES Pharma CJSC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-04-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25676">Universidade Federal de Minas Gerais</Company><Country id="BR">Brazil</Country><Drug id="79289">sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="25676">Universidade Federal de Minas Gerais</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1470">Respiratory system agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1062315">Pharmarare SA</Company><Country id="WO">World</Country><Drug id="71313">DasKloster 0249-01</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-30 00:00:00</LatestChange><ParentCompany id="1062315">Pharmarare SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CA">Canada</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-08-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022846">Nagoya City University</Company><Country id="JP">Japan</Country><Drug id="70208">glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-18 00:00:00</LatestChange><ParentCompany id="1022846">Nagoya City University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1022846">Nagoya City University</Company><Country id="JP">Japan</Country><Drug id="70208">glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-18 00:00:00</LatestChange><ParentCompany id="1022846">Nagoya City University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032157">PaxVax Inc</Company><Country id="US">US</Country><Drug id="72040">adenovirus 4-based vaccine (oral, tuberculosis), PaxVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-27 00:00:00</LatestChange><ParentCompany id="1032157">PaxVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86658">GA3 MEP-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81363">AEC/BC02</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-21 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20642">The University of Notre Dame du Lac</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="20642">The University of Notre Dame du Lac</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="89141">rBCG30 vaccine (improved version, tuberculosis), UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-29 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1017949">Novartis Institute for Tropical Diseases Pvt Ltd</Company><Country id="SG">Singapore</Country><Drug id="82584">tuberculosis therapy, NITD/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82584">tuberculosis therapy, NITD/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82584">tuberculosis therapy, NITD/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003379">Sichuan University</Company><Country id="CN">China</Country><Drug id="87680">SKLB-TB37</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-16 00:00:00</LatestChange><ParentCompany id="1003379">Sichuan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003379">Sichuan University</Company><Country id="CN">China</Country><Drug id="87680">SKLB-TB37</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-06-16 00:00:00</LatestChange><ParentCompany id="1003379">Sichuan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20639">University of New Mexico</Company><Country id="US">US</Country><Drug id="88384">peptides (tuberculosis), University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-24 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20639">University of New Mexico</Company><Country id="US">US</Country><Drug id="88384">peptides (tuberculosis), University of New Mexico/Science &amp; Technology Corporation @ UNM</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-24 00:00:00</LatestChange><ParentCompany id="20639">University of New Mexico</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20584">Harvard University</Company><Country id="US">US</Country><Drug id="86119">small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-01 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1090092">Liaoning Hongwuxing Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="89824">urea compounds (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-23 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="83093">Acetolactate synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="89914">antimycobacterials (Mycobacterium tuberculsosis infection), Astrazeneca</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-04-15 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-04-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1044432">Shanghai Zerun Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="81607">tuberculosis vaccine, Shanghai Zerun Biotech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-07 00:00:00</LatestChange><ParentCompany id="1048098">Yunnan Walvax Biotech Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="87132">anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-27 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062383">Chongqing Zhifei Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81037">Wei Ka</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1062383">Chongqing Zhifei Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80062">Ka Shu Ning</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80067">BCG vaccine (intradermal), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17639">Kaneka Corp</Company><Country id="JP">Japan</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="17639">Kaneka Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-02-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071336">Nanosystem Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="82299">rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-07 00:00:00</LatestChange><ParentCompany id="1071336">Nanosystem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1051">Unspecified enzyme modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21084">Howard Hughes Medical Institute</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="21084">Howard Hughes Medical Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1073552">PHARMACLON LLC</Company><Country id="RU">Russian Federation</Country><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1073552">PHARMACLON LLC</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1996-12-09 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-04-19 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KE">Kenya</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="JP">Japan</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2015-03-18 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CO">Colombia</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="IN">India</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="90122">DprE1 inhibitors (Mycobacterium tuberculosis infection), AstraZeneca</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-10 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003379">Sichuan University</Company><Country id="CN">China</Country><Drug id="95733">antituberculosis agents (tuberculosis) Sichuan University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-27 00:00:00</LatestChange><ParentCompany id="1003379">Sichuan University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-06-14 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1098970">Okklo Life Sciences BV</Company><Country id="NL">Netherlands</Country><Drug id="92087">OKL-3018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-31 00:00:00</LatestChange><ParentCompany id="1098970">Okklo Life Sciences BV</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="90381">anti-tuberculosis drugs (Mycobacterium tuberculosis infection), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26400">FIT Biotech Oyj Plc</Company><Country id="FI">Finland</Country><Drug id="66880">GTU-TB vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-09 00:00:00</LatestChange><ParentCompany id="26400">FIT Biotech Oyj Plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2000-02-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1009877">Chemical Diversity Research Institute Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1012947">ChemDiv Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24136">Cornell University</Company><Country id="US">US</Country><Drug id="86500">proteosome inhibitors (mycobacterium tuberculosis), Cornell University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-01 00:00:00</LatestChange><ParentCompany id="24136">Cornell University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20466">UK National Institute of Medical Research</Company><Country id="GB">UK</Country><Drug id="22154">DNA vaccine (tuberculosis), NIMR/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-10-13 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-02-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="21110">Karolinska Institutet</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7294">Antisense oligonucleotide inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="21110">Karolinska Institutet</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30837">Dartmouth-Hitchcock Medical Center</Company><Country id="US">US</Country><Drug id="90231">DAR-901</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-28 00:00:00</LatestChange><ParentCompany id="30837">Dartmouth-Hitchcock Medical Center</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-02-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071272">Cellworks Group Inc</Company><Country id="US">US</Country><Drug id="90432">CWGNC-4_1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-02 00:00:00</LatestChange><ParentCompany id="1071272">Cellworks Group Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20658">University of Pennsylvania</Company><Country id="US">US</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="20658">University of Pennsylvania</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1732">Energy metabolism modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="GB">UK</Country><Drug id="71615">energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-28 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="870">Glutamate receptor modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="18364">L-homoserine, Johns Hopkins</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-01-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21814">St Jude Children's Research Hospital</Company><Country id="US">US</Country><Drug id="33073">thiolactomycin analog, GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-08 00:00:00</LatestChange><ParentCompany id="21814">St Jude Children's Research Hospital</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5552">Helicase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="66922">UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-07-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-11-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LT">Lithuania</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EG">Egypt</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-10-29 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="ZA">South Africa</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PE">Peru</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82716">tuberculosis therapy, TB Alliance/Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82709">macrolides (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="225">IL-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="10997">PA-342</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-11-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 13:55:49</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="25210">Universidad de Zaragoza</Company><Country id="ZA">South Africa</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="25210">Universidad de Zaragoza</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="48741">Alanine racemase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007281">L2 Diagnostics Llc</Company><Country id="US">US</Country><Drug id="72479">alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-02 00:00:00</LatestChange><ParentCompany id="1007281">L2 Diagnostics Llc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="48741">Alanine racemase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007281">L2 Diagnostics Llc</Company><Country id="US">US</Country><Drug id="72479">alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-02 00:00:00</LatestChange><ParentCompany id="1007281">L2 Diagnostics Llc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="20226">Southern Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20226">Southern Research Institute</Company><Country id="US">US</Country><Drug id="67092">tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-22 00:00:00</LatestChange><ParentCompany id="20226">Southern Research Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="17962">Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-09-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-09-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1008113">GenomIdea Inc</Company><Country id="JP">Japan</Country><Drug id="60030">DNA vaccines (HJV vector, tuberculosis), GenomIdea</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-04-20 00:00:00</LatestChange><ParentCompany id="28514">AnGes MG Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="30365">Ubiquinol cytochrome C reductase 14 kDa inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="85970">Q-203, Qurient / Infectex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-02-06 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1885">Phospholipase A2 stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="33132">B-4128</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-07-08 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-03-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25323">University of Pretoria</Company><Country id="ZA">South Africa</Country><Drug id="33132">B-4128</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-07-08 00:00:00</LatestChange><ParentCompany id="25323">University of Pretoria</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-07-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73038">polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-09 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59776">ND-801</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1013076">NeED Pharmaceuticals Srl</Company><Country id="IT">Italy</Country><Drug id="59776">ND-801</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-21 00:00:00</LatestChange><ParentCompany id="1013076">NeED Pharmaceuticals Srl</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036156">Vaxil BioTherapeutics Ltd</Company><Country id="IL">Israel</Country><Drug id="66172">MTbuVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-25 00:00:00</LatestChange><ParentCompany id="1095293">Sheldonco Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="14365">Defensin modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-09-09 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054893">Medical Research Council Technology</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2941">Antidepressant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="17132">pascolizumab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-23 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27485">Phage Therapeutics Inc</Company><Country id="US">US</Country><Drug id="34469">bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="27485">Phage Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-06-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-08-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CH">Switzerland</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-09-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="70581">leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-17 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-10-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="476">Hyaluronic acid agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1052204">Beech Tree Labs Inc</Company><Country id="GB">UK</Country><Drug id="69033">ML-05</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-13 00:00:00</LatestChange><ParentCompany id="1052204">Beech Tree Labs Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76813">anti-tuberculosis therapeutics, Pro Bono Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-17 00:00:00</LatestChange><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76813">anti-tuberculosis therapeutics, Pro Bono Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-17 00:00:00</LatestChange><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="73547">Carbapenem</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="78977">DPR oxidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="82710">cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="82710">cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="72912">alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="70759">anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-12 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="82710">cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30118">Anacor Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="89753">anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-31 00:00:00</LatestChange><ParentCompany id="30118">Anacor Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="89970">inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-30 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="248">Lyase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ES">Spain</Country><Drug id="56373">isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1092461">Institute for Tuberculosis Research</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1092461">Institute for Tuberculosis Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006553">EyeGene Inc</Company><Country id="KR">South Korea</Country><Drug id="93723">anti-tuberculosis vaccine, EyeGene</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-30 00:00:00</LatestChange><ParentCompany id="1006553">EyeGene Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-08-15 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-09-22 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25530">esaT6 gene modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-06-10 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20579">University of Georgia</Company><Country id="US">US</Country><Drug id="95507">small molecule therapeutics (tuberculosis/HIV), University of Georgia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-28 00:00:00</LatestChange><ParentCompany id="20579">University of Georgia</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-01-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-08-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="938">Cytokine synthesis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-08-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="X0">Africa</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-12-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="MX">Mexico</Country><Drug id="19980">HE-2000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-28 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82660">DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17684">Korea Research Institute of Chemical Technology</Company><Country id="KR">South Korea</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="17684">Korea Research Institute of Chemical Technology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-01-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25513">Genesis Research and Development Corp Ltd</Company><Country id="NZ">New Zealand</Country><Drug id="40637">MED-1 vaccine (tuberculosis), Genesis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-04-30 00:00:00</LatestChange><ParentCompany id="25513">Genesis Research and Development Corp Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2009-04-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TH">Thailand</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="KR">South Korea</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="TR">Turkey</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-11-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CN">China</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="EU">EU</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-03-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="89337">recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="89337">recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19060">Pantoate beta alanine ligase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="88214">pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="88507">ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="30131">Janssen Diagnostics BVBA</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-05-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="30131">Janssen Diagnostics BVBA</Company><Country id="BE">Belgium</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="71209">DNA gyrase B inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20234">SRI International</Company><Country id="US">US</Country><Drug id="74814">gyrase B inhibitors (tuberculosis), SRI</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-02 00:00:00</LatestChange><ParentCompany id="20234">SRI International</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-11-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75084">Ag85A/B DNA vaccine (tuberculosis), Shanghai H&amp;G Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="75087">Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066884">Savine Therapeutics Pty Ltd</Company><Country id="AU">Australia</Country><Drug id="77428">TB SAVINE (cDNA vaccine, tuberculosis), Savine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-12-14 00:00:00</LatestChange><ParentCompany id="30212">BioDiem Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="KR">South Korea</Country><Drug id="78036">TB I series (tuberculosis infection), Qurient Therapeutics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-28 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20633">National University of Singapore</Company><Country id="SG">Singapore</Country><Drug id="77116">miRNA-like molecules (tuberculosis), NUS</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-06-20 00:00:00</LatestChange><ParentCompany id="20633">National University of Singapore</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1055897">Microbion Corp</Company><Country id="US">US</Country><Drug id="77124">MB-11, Microbion</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-17 00:00:00</LatestChange><ParentCompany id="1055897">Microbion Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15573">Epimmune Inc</Company><Country id="US">US</Country><Drug id="10406">Theradigm-tuberculosis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-12-09 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-06-22 14:36:07</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-02-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24897">Antibiotic Co</Company><Country id="BG">Bulgaria</Country><Drug id="10994">T9</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-01-02 00:00:00</LatestChange><ParentCompany id="24897">Antibiotic Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24897">Antibiotic Co</Company><Country id="BG">Bulgaria</Country><Drug id="10994">T9</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-01-02 00:00:00</LatestChange><ParentCompany id="24897">Antibiotic Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1997-10-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1541">Aminoglycoside antibiotic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-05-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24982">PathoGenesis Ltd</Company><Country id="US">US</Country><Drug id="11232">tobramycin (nebulized), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-05-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="135">DHFR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="135">DHFR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20593">Indiana University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20593">Indiana University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-01-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20569">Duquesne University</Company><Country id="US">US</Country><Drug id="12146">dihydrofolate reductase inhibitors, Duquesne/Indiana</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-04 00:00:00</LatestChange><ParentCompany id="20569">Duquesne University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20265">Nventa Biopharmaceuticals Corp</Company><Country id="CA">Canada</Country><Drug id="12954">vaccine (tuberculosis), StressGen</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2000-05-18 00:00:00</LatestChange><ParentCompany id="1011141">Akela Pharma Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-08-08 02:46:32</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="RU">Russian Federation</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X2">Asia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X2">Asia</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="PE">Peru</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="X0">Africa</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="ES">Spain</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15187">Systemic dermatological antibacterial product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="TZ">Tanzania</Country><Drug id="12978">moxifloxacin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-10 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2005-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-05-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1998-03-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1997-10-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="15184">Systemic antipsoriatic product</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><Drug id="11115">SRL-172</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-05-07 00:00:00</LatestChange><ParentCompany id="22356">Silence Therapeutics plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1995-10-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20939">Whitehead Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="20939">Whitehead Institute for Biomedical Research</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-08-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19267">Pasteur Merieux Connaught Canada</Company><Country id="US">US</Country><Drug id="12124">vaccine (BCG), Connaught/Whitehead</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-08-24 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="439">RNA synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24345">Harbor Therapeutics Inc</Company><Country id="US">US</Country><Drug id="15867">PP-29</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-07-02 00:00:00</LatestChange><ParentCompany id="24345">Harbor Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-07-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="142">Topoisomerase II inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2000-01-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20634">University of North Carolina</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="20634">University of North Carolina</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="9166">Nuclease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2638">Antiparasitic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1748">Fungicide</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17195">Immtech Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="16755">pafuramidine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-22 00:00:00</LatestChange><ParentCompany id="17195">Immtech Pharmaceuticals Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21048">Brigham &amp; Women's Hospital</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="21048">Brigham &amp; Women's Hospital</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1999-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21048">Brigham &amp; Women's Hospital</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="21048">Brigham &amp; Women's Hospital</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>1999-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12374">Lipid subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21048">Brigham &amp; Women's Hospital</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="21048">Brigham &amp; Women's Hospital</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25562">VacTex Corp</Company><Country id="US">US</Country><Drug id="15602">vaccine (tuberculosis), Procept</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26201">OriGenix Technologies Inc</Company><Country id="CA">Canada</Country><Drug id="32998">Mycobacterium tuberculosis therapeutics, OriGenix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-09-13 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-09-13 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26201">OriGenix Technologies Inc</Company><Country id="CA">Canada</Country><Drug id="32998">Mycobacterium tuberculosis therapeutics, OriGenix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-09-13 00:00:00</LatestChange><ParentCompany id="18210">Biowest Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-02-23 12:55:10</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20607">University of London</Company><Country id="GB">UK</Country><Drug id="35747">antibacterial protease inhibitors, Medivir/University of London</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2003-08-19 00:00:00</LatestChange><ParentCompany id="20607">University of London</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-08-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25333">Panacea Biotec Ltd</Company><Country id="IN">India</Country><Drug id="29616">Panacea-0394</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-20 00:00:00</LatestChange><ParentCompany id="25333">Panacea Biotec Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-07-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="32516">peptide vaccine (tuberculosis), Intercell/Sequella</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-30 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27753">Oxxon Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="42764">TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-02 00:00:00</LatestChange><ParentCompany id="23434">Oxford BioMedica plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006466">FASgen Inc</Company><Country id="US">US</Country><Drug id="49581">FAS-20013</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-25 00:00:00</LatestChange><ParentCompany id="1006466">FASgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33970">Mycobacterial antigen complex 85B modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="48499">HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-29 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-01-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-04-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="49162">LL-3858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-24 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21932">Lupin Ltd</Company><Country id="IN">India</Country><Drug id="51319">LL-4858</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-03-26 00:00:00</LatestChange><ParentCompany id="21932">Lupin Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-04-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21266">Ranbaxy Laboratories Ltd</Company><Country id="IN">India</Country><Drug id="46560">RBx-8700</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-05 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="48440">capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-03 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-11-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1042702">The Lilly TB Drug Discovery Initiative</Company><Country id="US">US</Country><Drug id="57219">N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="1042702">The Lilly TB Drug Discovery Initiative</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56371">InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-03-21 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="18476">MAPK gene modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7813">TLR-4 antagonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="55173">cadi-05</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ZA">South Africa</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ZA">South Africa</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1014222">Archivel Farma SL</Company><Country id="ES">Spain</Country><Drug id="57308">RUTI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="1014222">Archivel Farma SL</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-05-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28431">UMeWorld Ltd</Company><Country id="CA">Canada</Country><Drug id="53605">rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-08 00:00:00</LatestChange><ParentCompany id="28431">UMeWorld Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-07-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1040955">Oxford-Emergent Tuberculosis Consortium Ltd</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22182">University of Oxford</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="22182">University of Oxford</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-05-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1020621">TB-VAC</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1020621">TB-VAC</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="ZA">South Africa</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1011990">Emergent BioSolutions Inc</Company><Country id="SN">Senegal</Country><Drug id="55317">MVA-85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-07 00:00:00</LatestChange><ParentCompany id="1011990">Emergent BioSolutions Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-07 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28463">Intercell AG</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-03-02 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="NL">Netherlands</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-11-18 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="TZ">Tanzania</Country><Drug id="53784">Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-28 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1035256">Upstream Biosciences Inc</Company><Country id="CA">Canada</Country><Drug id="62917">antibacterial therapies (tuberculosis), Upstream Biosciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-01-10 00:00:00</LatestChange><ParentCompany id="1035256">Upstream Biosciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="57733">gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2006-12-31 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57737">antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-22 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2012-07-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17237">Institut Pasteur</Company><Country id="XW">Western Europe</Country><Drug id="61115">EthR inhibitors (mycobacterium tuberculosis), BioVersys</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-07-10 00:00:00</LatestChange><ParentCompany id="17237">Institut Pasteur</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1045576">Avanti Therapeutics</Company><Country id="WO">World</Country><Drug id="62573">tuberculosis vaccine, Avanti Therapeutics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="1045576">Avanti Therapeutics</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29830">Genexine Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="61171">GX-140</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-06-19 00:00:00</LatestChange><ParentCompany id="29830">Genexine Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-06-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032007">SinoBiomed Inc</Company><Country id="CN">China</Country><Drug id="61931">recombinant multivalent tuberculosis vaccine, SinoBiomed</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-01-06 00:00:00</LatestChange><ParentCompany id="1032007">SinoBiomed Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="33967">Mycobacterial antigen complex 85A modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75153">ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7294">Antisense oligonucleotide inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14240">Sarepta Therapeutics Inc</Company><Country id="US">US</Country><Drug id="71453">XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-01-05 00:00:00</LatestChange><ParentCompany id="14240">Sarepta Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="399">Hypoglycemic agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="791">Interleukin-1 converting enzyme inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047826">Omni Bio Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="66767">p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="1047826">Omni Bio Pharmaceutical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071272">Cellworks Group Inc</Company><Country id="US">US</Country><Drug id="90432">CWGNC-4_1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-02 00:00:00</LatestChange><ParentCompany id="1071272">Cellworks Group Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068863">Silvius Pharma</Company><Country id="RU">Russian Federation</Country><Drug id="76796">small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-14 00:00:00</LatestChange><ParentCompany id="1050615">ChemRar</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><Drug id="30799">Mycobacterium chaperonin inhibitors, University of Bristol</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-20 00:00:00</LatestChange><ParentCompany id="20544">University of Bristol</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-03-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="S">Suspended</Status><StatusDate>2000-02-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000375">Fudan University</Company><Country id="CN">China</Country><Drug id="67739">I-2906</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-01 00:00:00</LatestChange><ParentCompany id="DOL1000375">Fudan University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4917">Proteasome inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1085770">Harvard University Office of Technology Development</Company><Country id="US">US</Country><Drug id="86021">proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-21 00:00:00</LatestChange><ParentCompany id="20584">Harvard University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-11-08 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1084202">Valneva SE</Company><Country id="ZA">South Africa</Country><Drug id="74849">SSI H56-IC31</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-08 00:00:00</LatestChange><ParentCompany id="1084202">Valneva SE</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-05-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75158">Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&amp;G</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2009-05-22 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28907">Microbiotix Inc</Company><Country id="US">US</Country><Drug id="76748">MBX-600</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-20 00:00:00</LatestChange><ParentCompany id="28907">Microbiotix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="698">Nitric oxide donor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="MY">Malaysia</Country><Drug id="13323">pretomanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-05 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034429">Saurashtra University</Company><Country id="IN">India</Country><Drug id="95732">antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-28 00:00:00</LatestChange><ParentCompany id="1034429">Saurashtra University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1047078">Pharmstandard OJSC</Company><Country id="RU">Russian Federation</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="1047078">Pharmstandard OJSC</ParentCompany><Status id="R">Registered</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="CN">China</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="ZA">South Africa</Country><Drug id="51310">bedaquiline</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-03-18 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-07-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23137">Novartis AG</Company><Country id="US">US</Country><Drug id="91861">clofazimine (active tuberculosis), Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-06-25 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-06-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1088430">Sichuan Long March Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="96349">ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-11 00:00:00</LatestChange><ParentCompany id="1088430">Sichuan Long March Pharmaceutical Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-11-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19368">Bio Farma</Company><Country id="ID">Indonesia</Country><Drug id="96406">Lipovax-FliC-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-16 00:00:00</LatestChange><ParentCompany id="19368">Bio Farma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1995-07-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-09-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><Drug id="4229">rifabutin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-07 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-09-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1098970">Okklo Life Sciences BV</Company><Country id="NL">Netherlands</Country><Drug id="92087">OKL-3018</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-31 00:00:00</LatestChange><ParentCompany id="1098970">Okklo Life Sciences BV</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="FR">France</Country><Drug id="92356">FtsZ inhibitors (Mycobacterium tuberculosis infection), Sanofi/Colorado State University/Stony Brook University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-15 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-04-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="US">US</Country><Drug id="89824">urea compounds (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-23 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="89824">urea compounds (tuberculosis), TB Alliance/Sanofi</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-23 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><Drug id="89914">antimycobacterials (Mycobacterium tuberculsosis infection), Astrazeneca</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-04-15 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-04-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068758">California Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="1068758">California Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82662">diarylquinolines (tuberculosis), TB Alliance/J &amp; J/University of Auckland/University of Illinois at Chicago</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-03-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075626">Shenyang Hongqi Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-12-31 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-03-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="51201">Interferon gamma ligand</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><Country id="CU">Cuba</Country><Drug id="79519">interferon gamma follow-on biologic, CIGB/Heber Biotec</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-31 00:00:00</LatestChange><ParentCompany id="15353">Center for Genetic Engineering and Biotechnology</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2008-02-11 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80067">BCG vaccine (intradermal), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="26617">ATP-dependent Clp protease 1 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031362">NovoBiotic Pharmaceuticals LLC</Company><Country id="US">US</Country><Drug id="81058">lassomycin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031362">NovoBiotic Pharmaceuticals LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="86">Beta lactamase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="73547">Carbapenem</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24282">Albert Einstein College of Medicine</Company><Country id="US">US</Country><Drug id="79321">carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20704">Yeshiva University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-10-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1995-04-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17639">Kaneka Corp</Company><Country id="JP">Japan</Country><Drug id="8658">rifalazil</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-30 00:00:00</LatestChange><ParentCompany id="17639">Kaneka Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1996-11-04 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1086420">GlobalAcorn</Company><Country id="GB">UK</Country><Drug id="86659">GA4 NM-TB</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-17 00:00:00</LatestChange><ParentCompany id="1086420">GlobalAcorn</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="85774">TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-17 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><Drug id="78586">Mtb-DHFS inhibitor analogs (Mycobacterium tuberculosis infection), Syntrix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-01 00:00:00</LatestChange><ParentCompany id="1023036">Syntrix Biosystems Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><Drug id="78586">Mtb-DHFS inhibitor analogs (Mycobacterium tuberculosis infection), Syntrix</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-01 00:00:00</LatestChange><ParentCompany id="1023036">Syntrix Biosystems Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="79395">NBTIs (Mycobacterium tuberculosis infection), iThemba</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-13 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21102">Scripps Research Institute</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="21102">Scripps Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="49687">ATP synthase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068758">California Institute for Biomedical Research</Company><Country id="US">US</Country><Drug id="82643">ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-30 00:00:00</LatestChange><ParentCompany id="1068758">California Institute for Biomedical Research</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20642">The University of Notre Dame du Lac</Company><Country id="US">US</Country><Drug id="87600">antibacterial compounds (tuberculosis), Eli Lilly &amp; Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-11 00:00:00</LatestChange><ParentCompany id="20642">The University of Notre Dame du Lac</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="68490">Isocitrate lyase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="65567">isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="524">Adjuvant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="27376">Infectious Disease Research Institute</Company><Country id="US">US</Country><Drug id="68617">ID-93</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-09-20 00:00:00</LatestChange><ParentCompany id="27376">Infectious Disease Research Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="69074">BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049288">TVAX Biomedical LLC</Company><Country id="US">US</Country><Drug id="64503">autologous therapeutic vaccine, TVAX Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-03 00:00:00</LatestChange><ParentCompany id="1049288">TVAX Biomedical LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049788">iThemba Pharmaceuticals Pty Ltd</Company><Country id="ZA">South Africa</Country><Drug id="67090">nitroimidazole derivatives (tuberculosis), iThemba Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-06 00:00:00</LatestChange><ParentCompany id="1049788">iThemba Pharmaceuticals Pty Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002784">Adjuvantix Ltd</Company><Country id="GB">UK</Country><Drug id="64522">ADX40-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-21 00:00:00</LatestChange><ParentCompany id="1002784">Adjuvantix Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-21 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12372">Protein subunit vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17976">Novartis Vaccines and Diagnostics Ltd</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17976">Novartis Vaccines and Diagnostics Ltd</Company><Country id="GB">UK</Country><Drug id="66563">protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines &amp; Diagnostics/Statens Serum Institut</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-30 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-02-26 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20370">RecipharmCobra Biologics</Company><Country id="GB">UK</Country><Drug id="69165">tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-03-13 00:00:00</LatestChange><ParentCompany id="1058217">Recipharm AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67295">EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25058">VIB</Company><Country id="BE">Belgium</Country><Drug id="70144">tuberculosis vaccine, VIB/Ghent University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-07 00:00:00</LatestChange><ParentCompany id="22741">University of Antwerp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069870">Tianjin CanSino Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="71323">Ad5Ag85A</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-07 00:00:00</LatestChange><ParentCompany id="1069870">Tianjin CanSino Biotechnology Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054643">TB Drug Boost</Company><Country id="FR">France</Country><Drug id="67295">EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-20 00:00:00</LatestChange><ParentCompany id="1054643">TB Drug Boost</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3958">Protein kinase G inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031147">Vichem Chemie Ltd</Company><Country id="HU">Hungary</Country><Drug id="68370">PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-04-24 00:00:00</LatestChange><ParentCompany id="1031147">Vichem Chemie Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-04-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1062405">Qurient Therapeutics</Company><Country id="KR">South Korea</Country><Drug id="71430">Q-201, Qurient</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-17 00:00:00</LatestChange><ParentCompany id="1062405">Qurient Therapeutics</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-10-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1005984">Medisyn Technologies Inc</Company><Country id="US">US</Country><Drug id="65284">Gram positive antibacterials (tuberculosis infection), Medisyn Technologies</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-12-17 00:00:00</LatestChange><ParentCompany id="1005984">Medisyn Technologies Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1651">Protein tyrosine phosphatase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1058608">Aarden Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="69351">protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="1058608">Aarden Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70827">capreomycin (inhalant/powder, tuberculosis), Medicines in Need</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="66314">BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-05-04 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-05-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21502">Statens Serum Institut</Company><Country id="DK">Denmark</Country><Drug id="69824">H-56</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="21502">Statens Serum Institut</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="553">Folate synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="553">Folate synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="553">Folate synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><Drug id="71614">folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20702">Wayne State University</Company><Country id="US">US</Country><Drug id="67413">tubercuslosis program, B&amp;C Biopharm/Reyon Pharma/Wayne State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-07-21 00:00:00</LatestChange><ParentCompany id="20702">Wayne State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-07-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="71664">menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-05-27 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71667">malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&amp;M University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1034641">Shaheed Beheshti Medical University</Company><Country id="IR">Iran</Country><Drug id="65935">KBF-611</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-19 00:00:00</LatestChange><ParentCompany id="1034641">Shaheed Beheshti Medical University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="71742">TBA-354</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015456">The Institute of Microbiology Chinese Academy of Sciences</Company><Country id="CN">China</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="23863">Chinese Academy of Sciences</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="331">Protease inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71743">protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12366">Inactivated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-03-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1051823">Immodulon Therapeutics Limited</Company><Country id="AR">Argentina</Country><Drug id="70934">heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-26 00:00:00</LatestChange><ParentCompany id="1051823">Immodulon Therapeutics Limited</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18741">Chiron PathoGenesis</Company><Country id="US">US</Country><Drug id="11233">PA-647</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-10-01 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-11-02 15:31:09</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30043">LeukoMed Inc</Company><Country id="US">US</Country><Drug id="41819">LMP-420</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="30043">LeukoMed Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2011-11-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="LV">Latvia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EE">Estonia</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-09-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="61">Angiogenesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-04-28 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2014-10-29 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="6542">Mycolic acid synthase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="PE">Peru</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-07-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><Drug id="16545">delamanid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-13 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><Drug id="26493">posizolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-27 00:00:00</LatestChange><ParentCompany id="14190">AstraZeneca plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-12-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-03-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1020740">Vakzine Projekt Management GmbH</Company><Country id="DE">Germany</Country><Drug id="55569">VPM-1002</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-03-27 00:00:00</LatestChange><ParentCompany id="1020740">Vakzine Projekt Management GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="62968">SMAMPs (malaria), Fox Chase Chemical Diversity Center</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-02-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><Drug id="3365">Actimmune</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-19 00:00:00</LatestChange><ParentCompany id="19446">Roche Holding AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1011746">PolyMedix Inc</Company><Country id="US">US</Country><Drug id="63306">PMX-10072</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-09 00:00:00</LatestChange><ParentCompany id="1011746">PolyMedix Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19075">STAT3 gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-05-25 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="ZA">South Africa</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="ZA">South Africa</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="ES">Spain</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077737">Biofabri SL</Company><Country id="ES">Spain</Country><Drug id="89744">MTBVAC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-15 00:00:00</LatestChange><ParentCompany id="1077737">Biofabri SL</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031352">National Institute of Biomedical Innovation</Company><Country id="JP">Japan</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1031352">National Institute of Biomedical Innovation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1089867">Create Vaccine Co</Company><Country id="JP">Japan</Country><Drug id="89879">mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-26 00:00:00</LatestChange><ParentCompany id="1089867">Create Vaccine Co</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="19075">STAT3 gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-10-10 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23221">Agenus Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2002-10-15 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007281">L2 Diagnostics Llc</Company><Country id="US">US</Country><Drug id="72479">alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-02 00:00:00</LatestChange><ParentCompany id="1007281">L2 Diagnostics Llc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="64334">Phospho MurNAc pentapeptide transferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="71741">TL1 inhibitors (tuberculosis infection), Sequella</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-11-13 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="WO">World</Country><Drug id="86639">indazole derivatives (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-31 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1025">Glycosyltransferase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="78428">GlgE inhibitors (tuberculosis), MCRT</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-25 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036156">Vaxil BioTherapeutics Ltd</Company><Country id="IL">Israel</Country><Drug id="66172">MTbuVax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-02-25 00:00:00</LatestChange><ParentCompany id="1095293">Sheldonco Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-02-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="73038">polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-08-09 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25184">Yonsei University</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25184">Yonsei University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043700">PharMida AG</Company><Country id="CH">Switzerland</Country><Drug id="66235">targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-06 00:00:00</LatestChange><ParentCompany id="1011432">Midatech Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043700">PharMida AG</Company><Country id="CH">Switzerland</Country><Drug id="66235">targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-06 00:00:00</LatestChange><ParentCompany id="1011432">Midatech Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043700">PharMida AG</Company><Country id="CH">Switzerland</Country><Drug id="66235">targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-02-06 00:00:00</LatestChange><ParentCompany id="1011432">Midatech Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-02-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1540">Macrolide antibiotic</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1050467">Ascenion GmbH</Company><Country id="DE">Germany</Country><Drug id="82363">thuggacines (tuberculosis), Helmholtz</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-11-14 00:00:00</LatestChange><ParentCompany id="1050467">Ascenion GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="67683">T-Biovax</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-10-17 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-10-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="141">Topoisomerase I inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="71897">topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-06-27 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-06-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="7992">Heat shock protein modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18438">Medical Research Council (MRC)</Company><Country id="GB">UK</Country><Drug id="12867">vaccine (tuberculosis), MRC</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-03-16 00:00:00</LatestChange><ParentCompany id="18438">Medical Research Council (MRC)</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1015704">Shenzhen Neptunus Interlong Bio-Technique Co Ltd</Company><Country id="CN">China</Country><Drug id="80864">recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-10 00:00:00</LatestChange><ParentCompany id="1031729">Shenzhen Neptunus Bioengineering Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-09-10 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20562">Colorado State University</Company><Country id="US">US</Country><Drug id="86853">GI-19000</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-08-22 00:00:00</LatestChange><ParentCompany id="20562">Colorado State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-08-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1052204">Beech Tree Labs Inc</Company><Country id="GB">UK</Country><Drug id="69033">ML-05</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-13 00:00:00</LatestChange><ParentCompany id="1052204">Beech Tree Labs Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="18803">Keratinocyte modulator</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1052204">Beech Tree Labs Inc</Company><Country id="GB">UK</Country><Drug id="69033">ML-05</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-09-13 00:00:00</LatestChange><ParentCompany id="1052204">Beech Tree Labs Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20611">University of Maryland</Company><Country id="US">US</Country><Drug id="76032">tuberculosis vaccine, University of Maryland</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-10 00:00:00</LatestChange><ParentCompany id="20611">University of Maryland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1457">Protein kinase C modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30025">Cadila Pharmaceuticals Ltd</Company><Country id="IN">India</Country><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2009-10-31 00:00:00</LatestChange><ParentCompany id="30025">Cadila Pharmaceuticals Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2009-10-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="FR">France</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-06-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1091260">Abera Bioscience AB</Company><Country id="SE">Sweden</Country><Drug id="89342">multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-20 00:00:00</LatestChange><ParentCompany id="1091260">Abera Bioscience AB</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59382">Alpha crystallin inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15912">Finlay Institute</Company><Country id="CU">Cuba</Country><Drug id="72912">alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="15912">Finlay Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-09-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1833">Non-nucleoside reverse transcriptase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-06-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24735">Sarawak MediChem Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="9539">(+)-calanolide A</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2010-09-20 00:00:00</LatestChange><ParentCompany id="29393">Sarawak State Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2010-09-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1060211">Beijing Tuberculosis &amp; Thoracic Tumor Research Institute</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-06-30 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="104">Bacterial cell wall synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="78290">L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-05-24 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="74415">Transcriptional regulator protein EthR inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052531">BioVersys AG</Company><Country id="CH">Switzerland</Country><Drug id="92193">EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-27 00:00:00</LatestChange><ParentCompany id="1052531">BioVersys AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="NL">Netherlands</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-03-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="KE">Kenya</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="17254">Crucell NV</Company><Country id="ZA">South Africa</Country><Drug id="53975">AERAS-402</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-09-22 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2008-10-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12369">Recombinant bacterial vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="59144">AERAS-405</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-09-18 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-09-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25530">esaT6 gene modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21851">Polymun Scientific Immunobiologische Forschung GmbH</Company><Country id="AT">Austria</Country><Drug id="54201">tuberculosis vaccine (nasal, influenza virus carrier), Polymun</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-10 00:00:00</LatestChange><ParentCompany id="21851">Polymun Scientific Immunobiologische Forschung GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1006553">EyeGene Inc</Company><Country id="KR">South Korea</Country><Drug id="93723">anti-tuberculosis vaccine, EyeGene</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-30 00:00:00</LatestChange><ParentCompany id="1006553">EyeGene Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19829">SciClone Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="19829">SciClone Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-08-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29586">THERAMetrics Holding AG</Company><Country id="CH">Switzerland</Country><Drug id="95367">valorphin-containing peptides (tuberculosis), THERAMetrics Holding</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-16 00:00:00</LatestChange><ParentCompany id="29586">THERAMetrics Holding AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29586">THERAMetrics Holding AG</Company><Country id="CH">Switzerland</Country><Drug id="95367">valorphin-containing peptides (tuberculosis), THERAMetrics Holding</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-16 00:00:00</LatestChange><ParentCompany id="29586">THERAMetrics Holding AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20579">University of Georgia</Company><Country id="US">US</Country><Drug id="95507">small molecule therapeutics (tuberculosis/HIV), University of Georgia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-01-28 00:00:00</LatestChange><ParentCompany id="20579">University of Georgia</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-01-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004393">Myongji University (MJU)</Company><Country id="KR">South Korea</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1004393">Myongji University (MJU)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004393">Myongji University (MJU)</Company><Country id="KR">South Korea</Country><Drug id="71899">actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-24 00:00:00</LatestChange><ParentCompany id="1004393">Myongji University (MJU)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15745">Dong Wha Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="35974">DW-286</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-04-27 00:00:00</LatestChange><ParentCompany id="15745">Dong Wha Pharmaceutical Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-09-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-08-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-05-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="463">Ribosome binding agent</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20592">University of Illinois</Company><Country id="US">US</Country><Drug id="82340">replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-07-25 00:00:00</LatestChange><ParentCompany id="20592">University of Illinois</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-07-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="431">DNA gyrase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29411">The Global Alliance for TB Drug Development</Company><Country id="US">US</Country><Drug id="57730">quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="29411">The Global Alliance for TB Drug Development</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20649">Ohio State University</Company><Country id="US">US</Country><Drug id="17342">tuberculosis therapy, Ohio State University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="20649">Ohio State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1998-03-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="US">US</Country><Drug id="62397">AERAS-407 rBCG</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-11-27 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-11-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19595">Institute of Materia Medica Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Company><Country id="CN">China</Country><Drug id="57790">TBI-166</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-22 00:00:00</LatestChange><ParentCompany id="1066199">Chinese Academy of Medical Sciences &amp; Peking Union Medical College</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="US">US</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068619">Infectex</Company><Country id="RU">Russian Federation</Country><Drug id="31010">SQ-109</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-12-19 00:00:00</LatestChange><ParentCompany id="1061894">Maxwell Biotech Group</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-12-19 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><Drug id="56410">pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-06-18 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-06-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="5449">CDw137 modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29552">ApoVax Inc</Company><Country id="US">US</Country><Drug id="68211">ApoVax104-TB</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2015-01-05 00:00:00</LatestChange><ParentCompany id="29552">ApoVax Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2015-01-05 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="17424">vaccine (naked DNA, TB), Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-03-03 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-03-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054651">Medicine in Need</Company><Country id="US">US</Country><Drug id="70953">auxotroph vaccine (tuberculosis), Medicine in Need</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-24 00:00:00</LatestChange><ParentCompany id="1054651">Medicine in Need</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-04-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1538">Bacterial protein synthesis inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28087">Sequella Inc</Company><Country id="ZA">South Africa</Country><Drug id="11088">sutezolid</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-17 00:00:00</LatestChange><ParentCompany id="28087">Sequella Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25083">Pohang University of Science &amp; Technology</Company><Country id="KR">South Korea</Country><Drug id="53019">therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-24 00:00:00</LatestChange><ParentCompany id="25083">Pohang University of Science &amp; Technology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24317">Aquila Biopharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="22778">tuberculosis vaccine (CD1), Antigenics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-10-15 00:00:00</LatestChange><ParentCompany id="23221">Agenus Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-03-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="25527">Mycobacterium early secretory antigen modulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1066720">Shanghai H&amp;G Biotechnology Co</Company><Country id="CN">China</Country><Drug id="75156">HG856-SeV</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-01-17 00:00:00</LatestChange><ParentCompany id="1066720">Shanghai H&amp;G Biotechnology Co</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-06-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12371">Subunit vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-03-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-08-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1007376">Aeras Global TB Vaccine Foundation</Company><Country id="ZA">South Africa</Country><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/Aeras</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-08-26 00:00:00</LatestChange><ParentCompany id="1007376">Aeras Global TB Vaccine Foundation</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-08-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12363">Live attenuated bacterial vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-02-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25623">University of California Los Angeles</Company><Country id="US">US</Country><Drug id="9831">rBCG30, UCLA</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-02-17 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1004196">Verta Ltd</Company><Country id="RU">Russian Federation</Country><Drug id="25023">golotimod</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1004196">Verta Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-08-15 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row></Rowset>